Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Search

Page Path
HOME > Search
32 "Outcome"
Filter
Filter
Article category
Keywords
More +
Publication year
More +
Authors
More +
Funded articles
More +
Original Articles
Comparison of Long-term Oncological Outcome of Sentinel Lymph Node Mapping Methods (Dye-Only versus Dye and Radioisotope) in Breast Cancer Patients Following Neoadjuvant Chemotherapy
Jinyoung Byeon, Changjin Lim, Eunhye Kang, Ji-Jung Jung, Hong-Kyu Kim, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han
Received December 30, 2024  Accepted April 13, 2025  Published online April 15, 2025  
DOI: https://doi.org/10.4143/crt.2024.1253    [Accepted]
AbstractAbstract PDF
Purpose
Sentinel lymph node biopsy (SLNB) using dye and isotope (DUAL) is recommended over the dye-only (DYE) method after neoadjuvant chemotherapy (NCT) due to potentially lower false-negative rates. However, the long-term outcome of either method is unclear. We aimed to compare the long-term oncological outcomes of DYE versus DUAL SLNB methods in patients who received NCT.
Materials and Methods
In this retrospective cohort study, 893 patients who underwent SLNB following NCT and had pathologically negative lymph nodes were included. After propensity score matching for cT, cN, and pT stages, 280 patients were in the DYE group and 560 in the DUAL group. Indigo carmine was used for dye and Tc-99m antimony trisulfate for isotope mapping.
Results
Median follow-up was 75.6 months in the DYE group and 83.0 months in the DUAL group. Mean (±SD) number of harvested sentinel nodes was 6.7 (±3.4) and 6.7 (±3.8) in the DYE and DUAL groups (p=0.51). Five-year distant metastasis-free survival was 95.2% in DYE group and 93.3% in DUAL group (HR=1.45; 95% CI, 0.82–2.57; p=0.19). Disease-free survival (HR=0.97; 95% CI, 0.69–1.50; p=0.91) and overall survival (HR=0.98; 95% CI, 0.56–1.69; p=0.95) were not significantly different. Axillary recurrence rate was 1.8% and 2.5% in DYE and DUAL groups(p=0.64).
Conclusion
Long-term oncological outcomes did not significantly differ between DYE and DUAL SLNB methods. The dye-only method can be safely recommended for breast cancer patients who received NCT.
  • 56 View
  • 3 Download
Close layer
Ten-Year Follow-Up Clinical Outcomes and the Role of Adjuvant Chemotherapy in HER2-Positive Patients with Microinvasive Breast Cancer
Yeokyeong Shin, Soo-Young Lee, Hyehyun Jeong, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, BeomSeok Ko, Ji Sun Kim, Il Yong Chung, Hee Jin Lee, Gyungyub Gong, Sae Byul Lee, Jae Ho Jeong
Received November 22, 2024  Accepted March 3, 2025  Published online March 5, 2025  
DOI: https://doi.org/10.4143/crt.2024.1120    [Accepted]
AbstractAbstract PDF
Purpose
Although HER2 positivity is prevalent in microinvasive breast cancer (MIBC), data focused on HER2-positive MIBC are limited. We investigated the clinical course and long-term outcomes of HER2-positive MIBC and evaluated the role of adjuvant chemotherapy.
Materials and Methods
The study included patients with curatively resected pT1mi pN0 HER2-positive breast cancer between January 2000 and January 2020. Treatments and survival outcomes, including invasive breast cancer-free survival (IBCFS), distant recurrence-free survival (DRFS), and overall survival (OS) were analyzed.
Results
The analysis included 799 female patients. The median age was 51 years (range, 23–79), and 51.6% (n=412) were premenopausal. Multifocality was confirmed in 17.3% (n=138), and estrogen receptor (ER) positivity in 29.8% (n = 238). Adjuvant chemotherapy was administered to 17.5% (n=140), with doxifluridine in 96.4% of cases. One patient (0.1%) received trastuzumab. With a median follow-up of 119.0 months (95% CI, 114.0–127.0), the 8-year IBCFS, DRFS, and OS were 91.2% (95% CI, 89.1–93.3), 97.5% (95% CI, 96.4–98.7), and 98.8% (95% CI, 98.0–99.6), respectively. No significant differences were observed between patients with and without adjuvant chemotherapy. The lack of differences in IBCFS by chemotherapy was consistent across subgroups, including pre-/postmenopausal patients, grade 1-2/3 tumors, and ER-negative disease.
Conclusion
A clinically meaningful proportion of HER2-positive MIBC patients experience IBCFS events with long-term follow-up. Adjuvant chemotherapy did not improve survival, potentially due to the use of an outdated, ineffective regimen. The role of modern adjuvant regimens, particularly those incorporating HER2-targeted therapy, warrants further exploration.
  • 408 View
  • 34 Download
Close layer
General
Association between Tumor Size at the Time of Disease Progression and Survival Outcomes
Chi Hoon Maeng, Bum Jun Kim, Myung-Ju Ahn, In Sil Choi, Dae Young Zang, Bo-Hyung Kim, Minji Kwon, Dae Seog Heo, Bhumsuk Keam
Cancer Res Treat. 2025;57(2):362-368.   Published online October 22, 2024
DOI: https://doi.org/10.4143/crt.2024.690
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study evaluates the prognostic significance of tumor size at disease progression (PD) and depth of response (DOR) in cancer patients.
Materials and Methods
We performed post hoc analysis using data from six prospective clinical trials conducted by the Korean Cancer Study Group. Patients with tumor size at PD was categorized into ‘Mild PD’ and ‘Significant PD’ based on the cutoff values of relative change from baseline using maximally selected rank statistics. The overall survival (OS) and progression-free survival (PFS) were compared between PD and DOR categories.
Results
Among the 194 evaluable patients, 130 experienced PD. A 35.48% decrease from baseline in tumor size at PD was chosen for the cutoff between mild and significant PD for OS (mild PD: tumor size from the baseline ≤ −35.48%; significant PD > −35.48%). The mild PD had superior OS compared to the significant PD (25.8 vs. 12.8 months; Hazard ratio [HR] 0.47, 95% CI 0.266-0.843, p=0.009). When using an exploratory cutoff based on whether the tumor size was below vs. exceeded from the baseline (mild PD: tumor size from the baseline ≤ 0%; significant PD > 0%), OS remained significantly longer in the mild PD (17.1 vs. 11.8 months; HR 0.60, 95% CI 0.392-0.932, p=0.021). The greatest DOR was associated with the longest OS and PFS (p<0.001 for both).
Conclusion
Tumor size at PD and DOR were significant prognostic factors for progressive disease. Maintaining a sufficiently reduced tumor size even during PD was associated with better survival outcomes.
  • 797 View
  • 60 Download
Close layer
Lung and Thoracic cancer
Upfront Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy in Elderly Patients with Brain Metastases from Non–Small Cell Lung Cancer: A Retrospective Analysis of a 10-Year Bi-institutional Experience
Myungsoo Kim, Jihye Cha, Hun Jung Kim, Woo Chul Kim, Jeongshim Lee
Cancer Res Treat. 2025;57(1):47-56.   Published online July 3, 2024
DOI: https://doi.org/10.4143/crt.2024.223
AbstractAbstract PDFPubReaderePub
Purpose
Stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) are increasingly used as initial therapies for brain metastases (BM). We aimed to assess the outcomes of SRS/FSRT in patients aged ≥ 65 years who had 1-10 BM from non–small cell lung cancer (NSCLC).
Materials and Methods
We retrospectively reviewed 91 elderly NSCLC patients with 222 BM who were treated with SRS/FSRT at two institutions between 2010 and 2020. The primary endpoint was overall survival (OS) after SRS/FSRT. In addition, in-field local control (IFLC) within the treated field was evaluated. Statistical analysis was performed to identify the prognostic factors affecting OS and IFLC.
Results
During a median follow-up of 18 months, the median OS was 32 months. The 1- and 2-year survival rates were 69.8% and 56.1%, respectively. In multivariate analysis, the NSCLC-specific graded prognostic assessment (GPA) score (p=0.007) and administration of systemic therapy (p=0.039) were defined as prognosticators affecting OS. The median IFLC period was 31 months, and the 1- and 2-year IFLC rates were 75.9% and 57.6%, respectively. The total BM volume (p=0.042) significantly affected IFLC. No severe adverse events were reported after SRS/FSRT.
Conclusion
SRS/FSRT is an effective upfront treatment option for BM arising from NSCLC in elderly patients, with a good OS without severe side effects. Higher GPA score and active systemic treatment were associated with improved OS, indicating that elderly patients are significant candidates for SRS/FSRT.
  • 1,879 View
  • 167 Download
Close layer
General
Development and Feasibility Evaluation of Smart Cancer Care 2.0 Based on Patient-Reported Outcomes for Post-Discharge Management of Patients with Cancer
Jin Ah Kwon, Songsoo Yang, Su-Jin Koh, Young Ju Noh, Dong Yoon Kang, Sol Bin Yang, Eun Ji Kwon, Jeong-Wook Seo, Jin sung Kim, Minsu Ock
Cancer Res Treat. 2024;56(4):1040-1049.   Published online April 9, 2024
DOI: https://doi.org/10.4143/crt.2024.003
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
A “Smart Cancer Care” platform that integrates patient-reported outcomes (PROs) with management has been established in Korea. This study focused on improving health behaviors and connecting patients to welfare services by introducing and assessing the feasibility of “Smart Cancer Care 2.0,” an enhanced version designed for monitoring complications post-cancer treatment.
Materials and Methods
Smart Cancer Care 2.0 was developed by conducting a literature review and consulting with expert panels to identify symptoms or variables requiring monitoring and management guidelines based on the treatment type. Qualitative and quantitative surveys were conducted to assess the feasibility of the app and web system based on the experiences of patients with cancer and healthcare workers.
Results
A total of 81 symptoms or variables (chemotherapy-, surgery-, radiotherapy-, rehabilitation-, and health management-related) were selected for management in Smart Cancer Care 2.0. PROs for these symptoms were basically categorized into three severity grades: preventive management, self-treatment, and consultation with a healthcare worker or visit to a healthcare institution. The overall mean scores in the feasibility evaluation by patients and healthcare workers were 3.83 and 3.90 points, respectively, indicating high usefulness.
Conclusion
Smart Cancer Care 2.0 leverages the existing information and communication technologies–based platform, Smart Cancer Care, and further includes health behaviors and welfare services. Smart Cancer Care 2.0 may play a crucial role in establishing a comprehensive post-discharge management system for patients with cancer as it provides suitable interventions based on patients’ responses and allows the regularly collected PROs to be easily viewed for streamlined care.
  • 2,057 View
  • 121 Download
Close layer
Lung and Thoracic cancer
Clinical Outcome of Stereotactic Body Radiotherapy in Patients with Early-Stage Lung Cancer with Ground-Glass Opacity Predominant Lesions: A Single Institution Experience
Jeong Yun Jang, Su Ssan Kim, Si Yeol Song, Young Seob Shin, Sei Won Lee, Wonjun Ji, Chang-Min Choi, Eun Kyung Choi
Cancer Res Treat. 2023;55(4):1181-1189.   Published online March 21, 2023
DOI: https://doi.org/10.4143/crt.2022.1656
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The detection rate of early-stage lung cancer with ground-glass opacity (GGO) has increased, and stereotactic body radiotherapy (SBRT) has been suggested as an alternative to surgery in inoperable patients. However, reports on treatment results are limited. Therefore, we performed a retrospective study to investigate the clinical outcome after SBRT in patients with early-stage lung cancer with GGO-predominant tumor lesions at a single institution.
Materials and Methods
This study included 89 patients with 99 lesions who were treated with SBRT for lung cancer with GGO-predominant lesions that had a consolidation-to-tumor ratio of ≤0.5 at Asan Medical Center between July 2016 and July 2021. A median total dose of 56.0 Gy (range, 48.0–60.0) was delivered using 10.0–15.0 Gy per fraction.
Results
The overall follow-up period for the study was median 33.0 months (range, 9.9 to 65.9 months). There was 100% local control with no recurrences in any of the 99 treated lesions. Three patients had regional recurrences outside of the radiation field, and three had distant metastasis. The 1-year, 3-year, and 5-year overall survival rates were 100.0%, 91.6%, and 82.8%, respectively. Univariate analysis revealed that advanced age and a low level of diffusing capacity of the lungs for carbon monoxide were significantly associated with overall survival. There were no patients with grade ≥3 toxicity.
Conclusion
SBRT is a safe and effective treatment for patients with GGO-predominant lung cancer lesions and is likely to be considered as an alternative to surgery.

Citations

Citations to this article as recorded by  
  • Prognostic analysis of helical tomotherapy stereotactic body radiotherapy in multiple primary or second primary lung cancers
    Jintao Ma, Xiaohong Xu, Wenhan Huang, Yong Hu, Gang Chen, Jian He
    BMC Cancer.2025;[Epub]     CrossRef
  • Place de la radiothérapie en conditions stéréotaxiques dans les cancers bronchiques non à petites cellules localisés
    Catherine Durdux, Aurélia Alati
    Bulletin du Cancer.2025; 112(3): 3S31.     CrossRef
  • Recent Advancements in Minimally Invasive Surgery for Early Stage Non-Small Cell Lung Cancer: A Narrative Review
    Jibran Ahmad Khan, Ibrahem Albalkhi, Sarah Garatli, Marcello Migliore
    Journal of Clinical Medicine.2024; 13(11): 3354.     CrossRef
  • The clinical effect of thoracoscopic segmentectomy in the treatment of lung malignancies less than 2CM in diameter
    Yafeng Zhang, Renzhong Shi, Xiaoming Xia, Kaiyao Zhang
    Journal of Cardiothoracic Surgery.2024;[Epub]     CrossRef
  • Impact of ground-glass component on prognosis in early-stage lung cancer treated with stereotactic body radiotherapy via Helical Tomotherapy
    Jintao Ma, Shaonan Fan, Wenhan Huang, Xiaohong Xu, Yong Hu, Jian He
    Radiation Oncology.2024;[Epub]     CrossRef
  • 4,208 View
  • 227 Download
  • 7 Web of Science
  • 5 Crossref
Close layer
Hematologic malignancy
Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis
Jinchul Kim, Jinhyun Cho, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim
Cancer Res Treat. 2023;55(3):1031-1047.   Published online March 13, 2023
DOI: https://doi.org/10.4143/crt.2022.1658
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We intend to evaluate the efficacy of salvage treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) through meta-analysis.
Materials and Methods
R/R DLBCL trials were divided into two groups based on eligibility for autologous stem-cell transplantation (ASCT), and meta-analysis of each group was performed. Random effects models were used to estimate the 1-year progression-free survival (PFS) rate, and chimeric antigen receptor (CAR) T-cell therapy was used as reference treatment.
Results
Twenty-six ASCT-eligible cohorts from 17 studies comprising 2,924 patients and 59 ASCT-ineligible cohorts from 53 studies comprising 3,617 patients were included in the pooled analysis. In the ASCT-eligible group, the pooled 1-year PFS rate was 0.40 (95% confidence interval [CI], 0.15 to 0.65) for the CAR T-cell group and 0.34 (95% CI, 0.30 to 0.37) for the group with chemotherapy followed by ASCT intention. The two treatments were not significantly different in meta-regression analysis. In the ASCT-ineligible group, the pooled 1-year PFS was 0.40 (95% CI, 0.35 to 0.46) for CAR T-cell, and the highest primary outcome was 0.47 (95% CI, 0.37 to 0.57) for the tafasitamab group. CAR T-cell therapy showed significantly better outcomes than chemotherapy and therapies based on ibrutinib, lenalidomide, and selinexor. However, loncastuximab, polatuzumab plus bendamustine and rituximab, and the tafasitamab group showed no different efficacy than CAR T-cell therapy after adjusting for median number of previous lines of treatment.
Conclusion
Although several regimens were crudely grouped for classification, CAR T-cell therapy did not outperform chemotherapy followed by ASCT in the second-line setting or several recently developed agents in the ASCT-ineligible setting.

Citations

Citations to this article as recorded by  
  • Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma
    Loretta J. Nastoupil, Clark R. Andersen, Amy Ayers, Yucai Wang, Thomas M. Habermann, Dai Chihara, Brad S. Kahl, Brian K. Link, Jean L. Koff, Jonathon B. Cohen, Peter Martin, Izidore S. Lossos, Michele Stanchina, Sara Haddadi, Carla Casulo, Sabarish Ayyapp
    Clinical Lymphoma Myeloma and Leukemia.2025; 25(4): e183.     CrossRef
  • Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis
    Hanzala Ahmed Farooqi, Muhammad Saffi Ullah, Ahmed Raza, Zain Sadiq, Wardah Ali Shaikh, Rahmah Muhammad, Muhammad Shoaib Hussain
    Critical Reviews in Oncology/Hematology.2025; 207: 104611.     CrossRef
  • Efficacy and Safety of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Patients with Non-Hodgkin Lymphoma
    Abdur Jamil, Zaheer Qureshi, Rimsha Siddique, Faryal Altaf, Hamzah Akram, Rohma Jamil, Shehroz Aslam, Insija I. Selene
    American Journal of Clinical Oncology.2025;[Epub]     CrossRef
  • Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
    Ya Hwee Tan, Dok Hyun Yoon, Andrew J. Davies, Christian Buske, Yang Liang Boo, Nagavalli Somasundaram, Francesca Lim, Shin Yeu Ong, Anand Jeyasekharan, Koji Izutsu, Won Seog Kim, Jason Yongsheng Chan
    Discover Oncology.2025;[Epub]     CrossRef
  • Luteolin inhibits diffuse large B-cell lymphoma cell growth through the JAK2/STAT3 signaling pathway
    Xin-Zhuo Zhan, Yi-Wen Bo, Yu Zhang, Hai-Dong Zhang, Zhi-Hao Shang, Hui Yu, Xiao-Li Chen, Xiang-Tu Kong, Wan-Zhou Zhao, Timo Teimonen, Tao Liu, Meng-Yi Lu, Ye Yang, Shan-Liang Sun, Hai-Wen Ni
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol
    Mohammadreza Eslami, Mahdi Mehrabi, Mehrdad Payandeh, Fakhredin Saba, Chen Li
    PLOS ONE.2024; 19(8): e0308247.     CrossRef
  • Clinical scoring systems, molecular subtypes and baseline [18F]FDG PET/CT image analysis for prognosis of diffuse large B-cell lymphoma
    Zhuxu Sun, Tianshuo Yang, Chongyang Ding, Yuye Shi, Luyi Cheng, Qingshen Jia, Weijing Tao
    Cancer Imaging.2024;[Epub]     CrossRef
  • Targeting CD22 for B-cell hematologic malignancies
    Jia Xu, Wenjing Luo, Chenggong Li, Heng Mei
    Experimental Hematology & Oncology.2023;[Epub]     CrossRef
  • 7,911 View
  • 671 Download
  • 7 Web of Science
  • 8 Crossref
Close layer
Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
Jun Ho Yi, Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Youngil Koh, Jin Seok Kim, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Whan Jung Yun, Yong Park, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Dae-Sik Hong, Ho-Sup Lee, Gyeong-Won Lee, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2023;55(1):325-333.   Published online April 22, 2022
DOI: https://doi.org/10.4143/crt.2022.008
AbstractAbstract PDFPubReaderePub
Purpose
Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.
Materials and Methods
We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.
Results
Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).
Conclusion
In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population.

Citations

Citations to this article as recorded by  
  • PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
    Peng Sun, Hong Cen, Haiyan Yang, Rui Huang, Zhen Cai, Xuekui Gu, Hanying Bao, Zusheng Xu, Zuhong Xu, Zhi-Ming Li
    Cancer Cell International.2025;[Epub]     CrossRef
  • Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
    Ya Hwee Tan, Dok Hyun Yoon, Andrew J. Davies, Christian Buske, Yang Liang Boo, Nagavalli Somasundaram, Francesca Lim, Shin Yeu Ong, Anand Jeyasekharan, Koji Izutsu, Won Seog Kim, Jason Yongsheng Chan
    Discover Oncology.2025;[Epub]     CrossRef
  • Recent advances in cellular immunotherapy for lymphoid malignancies
    Haerim Chung, Hyunsoo Cho
    Blood Research.2023; 58(4): 166.     CrossRef
  • Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases
    Hongyu Chen, Junmin Wang, Caiyun Zhang, Peilun Ding, Shuxia Tian, Junming Chen, Guang Ji, Tao Wu
    Biomedicine & Pharmacotherapy.2022; 153: 113341.     CrossRef
  • 7,556 View
  • 353 Download
  • 3 Web of Science
  • 4 Crossref
Close layer
Pediatric cancer
Chronological Analysis of Acute Hematological Outcomes after Proton and Photon Beam Craniospinal Irradiation in Pediatric Brain Tumors
Gyu Sang Yoo, Jeong Il Yu, Sungkoo Cho, Youngyih Han, Yoonjin Oh, Do Hoon Lim, Hee Rim Nam, Ji-Won Lee, Ki-Woong Sung, Hyung Jin Shin
Cancer Res Treat. 2022;54(3):907-916.   Published online October 15, 2021
DOI: https://doi.org/10.4143/crt.2021.332
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to compare the early hematological dynamics and acute toxicities between proton beam craniospinal irradiation (PrCSI) and photon beam craniospinal irradiation (PhCSI) for pediatric brain tumors.
Materials and Methods
We retrospectively reviewed patients with pediatric brain tumors who received craniospinal irradiation (CSI). The average change in hemoglobin levels (ΔHbavg), absolute lymphocyte counts (ΔALCavg), and platelet counts (ΔPLTavg) from baseline values was evaluated and compared between the PrCSI and PhCSI groups at 1 and 2 weeks after the initiation of CSI, 1 week before and at the end of radiotherapy, and 3-4 weeks after the completion of radiotherapy using t test and mixed-model analysis.
Results
The PrCSI and PhCSI groups consisted of 36 and 30 patients, respectively. There were no significant differences in ΔHbavg between the two groups at any timepoint. However, ΔALCavg and ΔPLTavg were significantly lower in the PhCSI group than in PrCSI group at every timepoint, demonstrating that PrCSI resulted in a significantly lower rate of decline and better recovery of absolute lymphocyte and platelet counts. The rate of grade 3 acute anemia was significantly lower in the PrCSI group than in in the PhCSI group.
Conclusion
PrCSI showed a lower rate of decline and better recovery of absolute lymphocyte and platelet counts than PhCSI in the CSI for pediatric brain tumors. Grade 3 acute anemia was significantly less frequent in the PrCSI group than in the PhCSI group. Further large-scale studies are warranted to confirm these results.

Citations

Citations to this article as recorded by  
  • Pediatric CNS Radiation Oncology: Recent Developments and Novel Techniques
    Justin Oh, Samir Patel, Mary-Pat Schlosser, Andrew J. Arifin, Carol Oliveira, Anne-Marie Charpentier, Derek S. Tsang
    Current Oncology.2025; 32(3): 180.     CrossRef
  • Long-term effects of local radiotherapy on growth and vertebral features in children with high-risk neuroblastoma
    Kyungmi Yang, Joong Hyun Ahn, Sook-Young Woo, Sang Hoon Jung, Ki Woong Sung, Ji Won Lee, Do Hoon Lim
    BMC Pediatrics.2024;[Epub]     CrossRef
  • Comparison of Craniospinal Irradiation Using Proton Beams According to Irradiation Method and Initial Experience Treating Pediatric Patients
    Nobuyoshi Fukumitsu, Hikaru Kubota, Masayuki Mima, Yusuke Demizu, Takeshi Suzuki, Daiichiro Hasegawa, Yoshiyuki Kosaka, Atsufumi Kawamura, Toshinori Soejima
    Advances in Radiation Oncology.2023; 8(5): 101251.     CrossRef
  • Proton versus photon radiation therapy: A clinical review
    Zhe Chen, Michael M. Dominello, Michael C. Joiner, Jay W. Burmeister
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Shifting Strategies in the Treatment of Pediatric Craniopharyngioma
    Segev Gabay, Thomas E. Merchant, Frederick A. Boop, Jonathan Roth, Shlomi Constantini
    Current Oncology Reports.2023; 25(12): 1497.     CrossRef
  • 6,189 View
  • 139 Download
  • 6 Web of Science
  • 5 Crossref
Close layer
Head and Neck cancer
Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy: A Retrospective Study with 15-Year Follow-up
Lin Wang, Jingjing Miao, Huageng Huang, Boyu Chen, Xiao Xiao, Manyi Zhu, Yingshan Liang, Weiwei Xiao, Shaomin Huang, Yinglin Peng, Xiaowu Deng, Xing Lv, Weixiong Xia, Yanqun Xiang, Xiang Guo, Fei Han, Chong Zhao
Cancer Res Treat. 2022;54(1):118-129.   Published online June 7, 2021
DOI: https://doi.org/10.4143/crt.2021.101
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study was aimed to investigate long-term survivals and toxicities of early-stage nasopharyngeal carcinoma (NPC) in endemic area, evaluating the role of chemotherapy in stage II patients.
Materials and Methods
Totally 187 patients with newly diagnosed NPC and restaged American Joint Committee on Cancer/ International Union Against Cancer 8th T1-2N0-1M0 were retrospectively recruited. All received intensity-modulated radiotherapy (IMRT)±chemotherapy (CT) from 2001 to 2010.
Results
With 15.7-year median follow-up, 10-year locoregional recurrence-free survival, distant metastasis-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS) were 93.3%, 93.5%, 92.9% and 88.2%, respectively. Multivariable analyses showed cervical lymph nodes positive and pre-treatment prognostic nutritional index ≥ 52.0 could independently predict DMFS (p=0.036 and p=0.011), DSS (p=0.014 and p=0.026), and OS (p=0.002 and p < 0.001); Charlson comorbidity index < 3 points could predict DSS (p=0.011); age > 45 years (p=0.002) and pre-treatment lactate dehydrogenase ≥ 240 U/L (p < 0.001) predicted OS. No grade 4 late toxicity happened; grade 3 late toxicities included subcutaneous fibrosis (4.3%), deafness or otitis (4.8%), skin dystrophy (2.1%), and xerostomia (1.1%). No differences on survivals were shown between IMRT+CT vs. IMRT alone in stage II patients, even in T2N1M0 (p > 0.05). Unsurprising, patients in IMRT+CT had more acute gastrointestinal reaction, myelosuppression, mucositis, late ear toxicity, and cranial nerve injury (all p < 0.05) than IMRT alone group.
Conclusion
Superior tumor control and satisfying long-term outcomes could be achieved with IMRT in early-stage NPC with mild late toxicities. As CT would bring more toxicities, it should be carefully performed to stage II patients.

Citations

Citations to this article as recorded by  
  • Retrospective analysis of 1539 nasopharyngeal carcinoma cases: chemotherapy should not be excluded for non-Asian patients with T1-2N1M0 stage
    Xin-Yu Li, Chang-Ying Zhong, Hui-Xian Xu
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Genistein and chlorin E6-loaded versatile nanoformulation for remodeling the hypoxia-related tumor microenvironment and boosting photodynamic therapy in nasopharyngeal carcinoma treatment
    Qiang Zhou, Quazi T. H. Shubhra, Peng Lai, Jiayi Shi, Chenhao Fang, Qian Guo, Wanqing Li, Rui Chen, Xinkun Shen, Lina Huang, Xiaojun Cai, Sen Lin
    Advanced Composites and Hybrid Materials.2025;[Epub]     CrossRef
  • Vaccine-Based Immunotherapy for Oropharyngeal and Nasopharyngeal Cancers
    Daria Maria Filippini, Elisabetta Broseghini, Carlotta Liberale, Giulia Gallerani, Giambattista Siepe, Elisabetta Nobili, Manuela Ferracin, Gabriele Molteni
    Journal of Clinical Medicine.2025; 14(4): 1170.     CrossRef
  • Radiation oncology for the rhinologist
    Helena Levyn, Fan Yang, Nancy Y. Lee
    Current Opinion in Otolaryngology & Head & Neck Surgery.2024; 32(1): 5.     CrossRef
  • Examining patient-reported late toxicity and its association with quality of life and unmet need for symptom management among nasopharyngeal cancer survivors: a cross-sectional survey
    Victor C. W. Tam, Jerry C. F. Ching, Sindy S. T. Yip, Virginia H. Y. Kwong, Catherine P. L. Chan, Kenneth C. W. Wong, Shara W. Y. Lee
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Multifactorial clinical analysis of factors affecting necrosis of nasal septal mucosal flap after salvage surgery for recurrent nasopharyngeal carcinoma
    Qilin Gong, Huaying Li, Hui Liu, Youyuan Shi
    Scientific Reports.2024;[Epub]     CrossRef
  • Long noncoding RNA LINC00173 induces radioresistance in nasopharyngeal carcinoma via inhibiting CHK2/P53 pathway
    Jingjing Miao, Boyu Chen, Yunyun Xiao, Runda Huang, Xiao Xiao, Shunzhen Lu, Lu Zhang, Xuguang Wang, Ying Ouyang, Xiangfu Chen, Qiuyan Chen, Yanqun Xiang, Xiang Guo, Xiaowu Deng, Lin Wang, Haiqiang Mai, Chong Zhao
    Cancer Gene Therapy.2023; 30(9): 1249.     CrossRef
  • Therapeutic hyperthermia regulates complement C3 activation and suppresses tumor development through HSPA5/NFκB/CD55 pathway in nasopharyngeal carcinoma
    Chengcong Chen, Anbang Ren, Qi Yi, Jiazuo Cai, Muhammad Khan, Yunen Lin, Zhong Huang, Jie Lin, Jian Zhang, Wei Liu, Anan Xu, Yunhong Tian, YaWei Yuan, Ronghui Zheng
    Clinical and Experimental Immunology.2023; 213(2): 221.     CrossRef
  • Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)
    Huageng Huang, Yuyi Yao, Xinyi Deng, Zongyao Huang, Yungchang Chen, Zhao Wang, Huangming Hong, He Huang, Tongyu Lin
    International Journal of Oncology.2023;[Epub]     CrossRef
  • Quality of life and swallowing outcomes after early proactive swallowing rehabilitation by either transcutaneous neuromuscular electrical stimulation or exercise‐based swallowing training in patients with nasopharyngeal carcinoma after radiotherapy
    Peter K. M. Ku, Alexander C. Vlantis, Rita W. M. Wong, Thomas S. C. Hui, Thomas Law, Louisa K. Y. Ng, Eddy W. Y. Wong, W. T. Chang, David R. Johnson, Florence S. T. Mok, K. H. Wong, Victor Abdullah, Andrew van Hasselt, Kathy Y. S. Lee, Michael C. F. Tong
    Laryngoscope Investigative Otolaryngology.2023; 8(6): 1532.     CrossRef
  • Prognostic nutritional index and serum lactate dehydrogenase predict the prognosis of nasopharyngeal carcinoma patients who received intensity-modulated radiation therapy
    Chunxia Zhang, Zhouwei Zhan, Yunxiang Fang, Yuanyuan Ruan, Mingan Lin, Zhisen Dai, Yanping Zhang, Shanshan Yang, Shuxiang Xiao, Bijuan Chen
    Journal of Cancer Research and Clinical Oncology.2023; 149(20): 17795.     CrossRef
  • A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma
    Yao-Can Xu, Kai-Hua Chen, Zhong-Guo Liang, Xiao-Dong Zhu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Minimally Invasive Surgery for Early-Stage Nasopharyngeal Carcinoma
    Jinping Liu, Zesheng Zeng, Dingting Wang, Gang Qin
    Journal of Craniofacial Surgery.2022; 33(8): e834.     CrossRef
  • External Validation of a Nomogram to Predict Survival and Benefit of Concurrent Chemoradiation for Stage II Nasopharyngeal Carcinoma
    Pui-Lam Yip, Shing-Fung Lee, Cheuk-Wai Horace Choi, Po-Chung Sunny Chan, Ka-Wai Alice Cheung, Chung-Hang James Chow, Ka-Man Cheung, Wing-Yu Jessica Lai, Ho-Fun Victor Lee, Ka-On Lam, Chi-Leung Chiang, Chun-Yin Edwin Wong, Ming-Chun Darren Poon, Macy Tong,
    Cancers.2021; 13(17): 4286.     CrossRef
  • 7,510 View
  • 174 Download
  • 15 Web of Science
  • 14 Crossref
Close layer
Pediatric cancer
Absolute Neutrophil Count after the First Chemotherapy Cycle as a Surrogate Marker for Treatment Outcomes in Patients with Neuroblastoma
Ji Won Lee, Joon Seol Bae, Jin Ho Kim, Hee Won Cho, Hee Young Ju, Keon Hee Yoo, Hong Hoe Koo, Sook-young Woo, Seonwoo Kim, Ki Woong Sung
Cancer Res Treat. 2022;54(1):259-268.   Published online April 12, 2021
DOI: https://doi.org/10.4143/crt.2021.010
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We performed this study to determine whether the degree of neutropenia after the first chemotherapy cycle can be used as a surrogate marker of individual susceptibility to chemotherapeutic agents affecting treatment outcome in patients with neuroblastoma.
Materials and Methods
The study included 313 patients who received the first cycle chemotherapy with a CEDC (cisplatin+etoposide+doxorubicin+cyclophosphamide) regimen and had absolute neutrophil count (ANC) data available. The cumulative incidences of progression and treatment-related mortality (TRM) were estimated. To identify genetic variations associated with the ANC, a genome-wide association study (GWAS) was performed.
Results
An ANC of 32.5/μL was determined as the cutoff point to categorize patients into the good and poor prognosis subgroups in terms of progression. Patients with a high nadir ANC had a higher cumulative incidence of progression than those with a low nadir ANC (p < 0.001). In multivariate analysis, high nadir ANC, age, bone marrow involvement, and unfavorable histology were poor prognostic factors. With regard to the TRM, patients with a low nadir ANC (ANC < 51.0/μL) had a higher cumulative incidence of TRM than those with a high nadir ANC (p=0.010). In GWAS, single-nucleotide polymorphisms of LPHN2 and CRHR1 were significantly associated with the nadir ANC.
Conclusion
In neuroblastoma patients, the degree of neutropenia after the first chemotherapy cycle can be used as a surrogate marker to predict an individual’s susceptibility to chemotherapeutic agents. Tailoring of treatment based on the degree of neutropenia needs to be considered.

Citations

Citations to this article as recorded by  
  • Impact of 10% Dose Reductions and Duration of Treatment Delays in the Management of Chemotherapy‐Induced Neutropenia in Dogs Treated With Common Chemotherapy Protocols: A Single‐Centre Experience
    Suzanne Busser, Laura Blackwood, Constanza Pereira, Margo Chase‐Topping, Spela Bavcar, Quentin Fournier
    Veterinary and Comparative Oncology.2024; 22(4): 542.     CrossRef
  • Targeting the myeloid microenvironment in neuroblastoma
    Marjolein C. Stip, Loes Teeuwen, Miranda P. Dierselhuis, Jeanette H. W. Leusen, Daniëlle Krijgsman
    Journal of Experimental & Clinical Cancer Research.2023;[Epub]     CrossRef
  • 6,659 View
  • 164 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Head and Neck cancer
Oncological and Functional Outcomes of Larynx-preserving Surgery for Hypopharyngeal Cancer: A Comparison with Definitive Radiation-based Treatment
Donghyeok Kim, Nalee Kim, Sungmin Koh, Man Ki Chung, Young-Ik Son, Dongryul Oh, Han-Sin Jeong, Yong Chan Ahn
Cancer Res Treat. 2022;54(1):84-95.   Published online March 26, 2021
DOI: https://doi.org/10.4143/crt.2020.1197
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Larynx-preserving surgery (LPS) have recently gained popularity and achieved comparable oncologic outcomes to conventional radical surgery for localized hypopharyngeal cancer (HPC). In the current study, the role of LPS has been assessed thoroughly in comparison with upfront radiation therapy (RT).
Materials and Methods
We retrospectively reviewed 185 candidates for LPS with cT1-2 disease; 59 patients underwent upfront LPS while 126 patients received upfront RT, respectively. Oncological and functional outcomes were investigated and compared.
Results
Following LPS, safe margin (≥ 5 mm) was achieved in 37.3% of patients. Overall, better clinical outcomes at 5 years were achieved following upfront LPS than those following upfront RT: overall survival (OS) (72.7% vs. 59.0%, p=0.045), disease-free survival (DFS) (59.8% vs. 45.0%, p=0.039), and functional laryngeal preservation (100% vs. 89.7%, p=0.010). Although similar outcomes were observed in patients with cT1 disease, better 5-year DFS was achieved following upfront LPS in patients with cT2 disease (57.0% vs. 36.4%, p=0.023) by virtue of better local control. Despite frequent cN2-3 disease in upfront LPS group, comparable outcomes were observed between upfront RT and LPS group. However, multivariable analyses revealed that performance status and double primary cancer diagnosed within 6 months of HPC diagnosis affected OS significantly, while treatment modality per se did not.
Conclusion
Although upfront LPS could provide better local control than upfront RT in patients with cT2 disease, overall outcomes were comparable following either modality. Treatment selection of larynx-preserving approach for HPC should be individualized based on tumor and patient factors.

Citations

Citations to this article as recorded by  
  • In Reply to Liu and Luo
    Kangpyo Kim, Yong Chan Ahn
    International Journal of Radiation Oncology*Biology*Physics.2024; 118(1): 308.     CrossRef
  • The role and clinical significance of microRNA-29a-3p in the development of hypopharyngeal carcinoma
    Tao Liu, Detao Ding, Wei Wang, Yungang Wu, Dengdian Ma, Miaomiao Liu, Ziqiao Tan, Jing Yao, Xiaoyu Li
    Brazilian Journal of Otorhinolaryngology.2023; 89(3): 401.     CrossRef
  • Survival and swallowing function outcome impact factors analysis of surgery-oriented comprehensive treatment for hypopharyngeal cancer in a series of 122 patients
    Wan-Xin Li, Yan-Bo Dong, Cheng Lu, Patrick J. Bradley, Liang-Fa Liu
    Ear, Nose & Throat Journal.2022; 101(8): 532.     CrossRef
  • 7,505 View
  • 166 Download
  • 4 Web of Science
  • 3 Crossref
Close layer
Lung Cancer
Clinical Significance of Acute Kidney Injury in Lung Cancer Patients
Semin Cho, Eunjeong Kang, Ji Eun Kim, U Kang, Hee Gyung Kang, Minsu Park, Kwangsoo Kim, Dong Ki Kim, Kwon Wook Joo, Yon Su Kim, Hyung-Jin Yoon, Hajeong Lee
Cancer Res Treat. 2021;53(4):1015-1023.   Published online January 18, 2021
DOI: https://doi.org/10.4143/crt.2020.1010
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Acute kidney injury (AKI) in cancer patients is associated with increased morbidity and mortality. The incidence of AKI in lung cancer seems to be relatively higher compared with other solid organ malignancies, although its impact on patient outcomes remains unclear.
Materials and Methods
The patients newly diagnosed with lung cancer from 2004 to 2013 were enrolled in this retrospective cohort study. The patients were categorized according to the presence and severity of AKI. We compared all-cause mortality and long-term renal outcome according to AKI stage.
Results
A total of 3,202 patients were included in the final analysis. AKI occurred in 1,783 (55.7%) patients during the follow-up period, with the majority having mild AKI stage 1 (75.8%). During the follow-up of 2.6±2.2 years, total 1,251 patients (53.7%) were died and 5-year survival rate was 46.9%. We found that both AKI development and severity were independent risk factors for all-cause mortality in lung cancer patients, even after adjustment for lung cancer-specific variables including the stage or pathological type. In addition, patients suffered from more severe AKI tend to encounter de novo chronic kidney disease development, worsening kidney function, and end-stage kidney disease progression.
Conclusion
In this study, more than half of the lung cancer patients experienced AKI during their diagnosis and treatment period. Moreover, AKI occurrence and more advanced AKI were associated with a higher mortality risk and adverse kidney outcomes.

Citations

Citations to this article as recorded by  
  • Acute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials
    Isabela Gonçalves Lima, Isabele Benck Usiro Cabral da Silva, Vitória Carpentieri Pípolo, Vinicius Daher Alvares Delfino, Paulo Roberto Bignardi
    Immunopharmacology and Immunotoxicology.2024; 46(4): 470.     CrossRef
  • Prevalence of kidney disease in patients with different types of cancer or hematological malignancies: a cross-sectional study
    Feng Wu, Shiyuan Wang, Jialing Zhang, Peixin Wang, Aihua Zhang
    International Urology and Nephrology.2024; 56(12): 3835.     CrossRef
  • Protective effect of reduced glutathione on acute kidney injury in lung cancer patients treated with cisplatin: a retrospective cohort study
    Ying Huang, Yang Li, Xialian Xu, Jie Teng, Xiaoqiang Ding, Jiarui Xu
    Renal Failure.2024;[Epub]     CrossRef
  • Association between renal dysfunction and outcomes of lung cancer: A systematic review and meta‑analysis
    Huijuan Qian, Si Li, Ziyun Hu
    Oncology Letters.2024;[Epub]     CrossRef
  • Leveraging Explainable Machine Learning to Uncover the Association between Risk Factors and Major Cancers: Cancer Risk Factor Association Study (Preprint)
    Xiayuan Huang, ShuShun Ren, Xinyue Mao, Serena Chen, Elle Chen, Yuqi He, Yun Jiang
    JMIR Cancer.2024;[Epub]     CrossRef
  • Association and prediction of red blood cell distribution width to albumin ratio in all-cause mortality of acute kidney injury in critically ill patients
    Chen Gao, Longkai Peng
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Point of care ultrasonography in onco-nephrology: A stride toward better physical examination
    Bhavna Bhasin-Chhabra, Abhilash Koratala
    World Journal of Nephrology.2023; 12(2): 29.     CrossRef
  • Protocolo diagnóstico y tratamiento de la nefropatía en los pacientes con neoplasia sólida
    Rodríguez Doyágüez, M.P. Morán Magro, C.M. Durán López, P. Martínez Miguel
    Medicine - Programa de Formación Médica Continuada Acreditado.2023; 13(82): 4870.     CrossRef
  • 7,688 View
  • 194 Download
  • 6 Web of Science
  • 8 Crossref
Close layer
Genitourinary Cancer
Effects of Complete Bladder Cuff Removal on Oncological Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
Hyunsoo Ryoo, Jungyu Kim, Taejin Kim, Minyong Kang, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Hyun Hwan Sung
Cancer Res Treat. 2021;53(3):795-802.   Published online December 28, 2020
DOI: https://doi.org/10.4143/crt.2020.919
AbstractAbstract PDFPubReaderePub
Purpose
This study aimed to evaluate the effects of bladder cuff method on oncological outcomes in patients who underwent radical nephroureterectomy (RNU) for upper tract urothelial carcinoma.
Materials and Methods
The records of 1,095 patients treated with RNU performed at our hospital between 1994 and 2018 were retrospectively reviewed; 856 patients with no bladder tumor history were enrolled in the present study. The management of bladder cuff was divided into two categories: extravesical ligation (EL) or transvesical resection (TR). Survival was analyzed using the Kaplan-Meier method and Cox regression analyses were performed to determine which factors were associated with intravesical recurrence (IVR)–free survival (IVRFS), cancer-specific survival (CSS), and overall survival (OS).
Results
The mean patient age was 64.8 years and the median follow-up was 37.7 months. Among the 865 patients, 477 (55.7%) underwent the TR and 379 (44.3%) the EL. Significantly higher IVRFS (p=0.001) and OS (p=0.013) were observed in the TR group. In multivariable analysis, IVR, CSS, and OS were independently associated with the EL. Among 379 patients treated with the EL, eight underwent remnant ureterectomy. Based on radical cystectomy–free survival, significant difference was not observed between the two groups. However, significantly higher IVRFS was observed in the TR group when the tumor was located in the renal pelvis.
Conclusion
Intramural complete excision of the distal ureter during RNU should be the gold standard approach compared with EL for the management of distal ureter in terms of oncological outcomes.

Citations

Citations to this article as recorded by  
  • Single Early Intravesical Instillation of Epirubicin for Preventing Bladder Recurrence after Nephroureterectomy in Upper Urinary Tract Urothelial Carcinoma
    Jong Hoon Lee, Chung Un Lee, Jae Hoon Chung, Wan Song, Minyong Kang, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Hwan Sung
    Cancer Research and Treatment.2024; 56(3): 877.     CrossRef
  • Violation of onco-surgical principles is associated with survival outcomes in upper tract urothelial carcinomas after radical nephroureterectomy
    Ioannis Patras, Johan Abrahamsson, Axel Gerdtsson, Martin Nyberg, Ymir Saemundsson, Elin Ståhl, Anne Sörenby, Åsa Warnolf, Johannes Bobjer, Fredrik Liedberg
    Scandinavian Journal of Urology.2024; 59: 131.     CrossRef
  • Differential effect of surgical technique on intravesical recurrence after radical nephroureterectomy in patients with upper tract urothelial cancer: a systematic review and Meta-analysis
    Ichiro Tsuboi, Akihiro Matsukawa, Mehdi Kardoust Parizi, Jakob Klemm, Robert J Schulz, Anna Cadenar, Stefano Mancon, Sever Chiujdea, Tamás Fazekas, Marcin Miszczyk, Ekaterina Laukhtina, Tatsushi Kawada, Satoshi Katayama, Takehiro Iwata, Kensuke Bekku, Koi
    World Journal of Urology.2024;[Epub]     CrossRef
  • The impact of bladder cuff excision on outcomes after nephroureterectomy for upper tract urothelial carcinoma: An analysis of the ROBUUST 2.0 registry
    Courtney Yong, James E. Slaven, Zhenjie Wu, Vitaly Margulis, Hooman Djaladat, Alessandro Antonelli, Giuseppe Simone, Raj Bhanvadia, Alireza Ghoreifi, Farshad Sheybaee Moghaddam, Francesco Ditonno, Gabriele Tuderti, Stephan Bronimann, Sohail Dhanji, Benjam
    Urologic Oncology: Seminars and Original Investigations.2024; 42(11): 373.e1.     CrossRef
  • A new nomogram for predicting extraurothelial recurrence in patients with upper urinary tract urothelial carcinoma following radical nephroureterectomy
    Hao Wu, Dan Jia, Xianyu Dai, Hongliang Cao, Fulin Wang, Tong Yang, Lei Wang, Tao Xu, Baoshan Gao
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Perioperative and oncological outcomes of distal ureter management during nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and meta-analysis
    Andrea GALLIOLI, Michael BABOUDJIAN, Pietro DIANA, Marco MOSCHINI, Evanguelos XYLINAS, Francesco DEL GIUDICE, Ekaterina LAUKHTINA, Francesco SORIA, Andrea MARI, José D. SUBIELA, Mathieu ROUY, Angelo TERRITO, Giuseppe BASILE, Joan PALOU, Benjamin PRADERE,
    Minerva Urology and Nephrology.2023;[Epub]     CrossRef
  • Predicting and Decreasing Bladder Tumor Recurrence Following Nephroureterectomy
    Hiroko Miyagi, Elizabeth A. Di Valerio, Padraic O’Malley, Wayne G. Brisbane, Li-Ming Su, Paul L. Crispen
    Frontiers in Urology.2022;[Epub]     CrossRef
  • Inadvertent radical nephrectomy leads to worse prognosis in renal pelvic urothelial carcinoma patients: A propensity score-matched study
    Feixiang Wu, Pan Zhang, Lingxun Li, Shiqing Lin, Jianhong Liu, Yi Sun, Yuanlong Wang, Chengjun Luo, Yu Huang, Xiao Yan, Meng Zhang, Guixi Liu, Kun Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • 7,019 View
  • 152 Download
  • 8 Web of Science
  • 8 Crossref
Close layer
Head and Neck Cancer
Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area
Ji-Jin Yao, Li Lin, Tian-Sheng Gao, Wang-Jian Zhang, Wayne R. Lawrence, Jun Ma, Ying Sun
Cancer Res Treat. 2021;53(3):657-670.   Published online December 7, 2020
DOI: https://doi.org/10.4143/crt.2020.899
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to develop web-based nomograms to precisely predict survival outcomes in patients with non-metastatic nasopharyngeal carcinoma (NPC) in an endemic area.
Materials and Methods
A total of 10,126 patients who underwent radical intensity-modulated radiotherapy at Sun Yat-sen University Cancer Center (SYSUCC) from 2009 to 2015 were analyzed. We assigned patients into a training cohort (SYSUCC-A, n=6,751) and an internal validation cohort (SYSUCC-B, n=3,375) based on computer-generated random numbers. Patients collected from Wuzhou Red Cross Hospital (WZRCH) between 2012 and 2015 were used as the independent external validation cohort (WZRCH, n=450). Concordance index (C-index) was used to determine predictive accuracy and discriminative ability for the nomogram. The web-based clinicopathologic prediction models for predicting survival were based on Cox regression.
Results
The C-indexes for SYSUCC-A, SYSUCC-B, and WZRCH cohorts for the established nomograms to predict 3-year overall survival (OS) was 0.736, 0.715, and 0.691. Additionally, C-indexes to predict 3-year distant metastasis-free survival (DMFS) was 0.717, 0.706, and 0.686, disease-free survival (DFS) was 0.713, 0.697, and 0.656, local relapse-free survival was 0.695, 0.684, and 0.652, and regional relapse-free survival was 0.672, 0.650, and 0.616. The calibration plots showed great agreement between nomogram-predicted 3-year survival outcomes and actual 3-year survival outcomes. Moreover, C-indexes of the nomograms for OS, DMFS, and DFS were significantly superior than TNM stage (p< 0.001 for all).
Conclusion
These user-friendly nomograms can precisely predict survival endpoints in patients with non-metastatic NPC. They may serve as a useful tool for providing patient counseling and help physicians to make individual follow-up plans.

Citations

Citations to this article as recorded by  
  • Adverse prognosis of nasopharyngeal carcinoma following long-term exposure to multiple air pollutants
    Xiao Lin, Yanan Jin, Jijin Yao, Xurui Sun, Tian Tian, Zhiqiang Li, Shimin Chen, Jie Jiang, Weihua Hu, Yuantao Hao, Liangping Xia, Wangjian Zhang
    Environmental Chemistry Letters.2024; 22(1): 21.     CrossRef
  • The development and external validation of a web-based nomogram for predicting overall survival with Ewing sarcoma in children
    Yi Chen, Zirui Liu, Yaobin Wang, Hongwei Zhan, Jinmin Liu, Yongkang Niu, Ao Yang, Fei Teng, Jinfeng Li, Bin Geng, Yayi Xia
    Journal of Children's Orthopaedics.2024; 18(2): 236.     CrossRef
  • The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis
    Ya-Nan Jin, Meng-Yun Qiang, Ying Wang, Yu-Jing Lin, Ren-Wei Jiang, Wan-Wei Cao, Wang-Jian Zhang, Si-Yang Wang, Hong-Yu Zhang, Ji-Jin Yao
    Cancer Immunology, Immunotherapy.2024;[Epub]     CrossRef
  • Potential causal links of long‐term exposure to PM2.5 and its chemical components with the risk of nasopharyngeal carcinoma recurrence: A 10‐year cohort study in South China
    Xurui Sun, Xiao Lin, Jijin Yao, Tian Tian, Zhiqiang Li, Shimin Chen, Weihua Hu, Jie Jiang, Hui Tang, Huanle Cai, Tong Guo, Xudan Chen, Zhibing Chen, Man Zhang, Yongqing Sun, Shao Lin, Yanji Qu, Xinlei Deng, Ziqiang Lin, Liangping Xia, Yanan Jin, Wangjian
    International Journal of Cancer.2024; 155(9): 1558.     CrossRef
  • ALYREF promotes the metastasis of nasopharyngeal carcinoma by increasing the stability of NOTCH1 mRNA
    Yanan Jin, Jijin Yao, Jianchang Fu, Qitao Huang, Yilin Luo, Yafei You, Wangjian Zhang, Qian Zhong, Tianliang Xia, Liangping Xia
    Cell Death & Disease.2024;[Epub]     CrossRef
  • The continuous improvement of digital assistance in the radiation oncologist’s work: from web-based nomograms to the adoption of large-language models (LLMs). A systematic review by the young group of the Italian association of radiotherapy and clinical o
    Antonio Piras, Ilaria Morelli, Riccardo Ray Colciago, Luca Boldrini, Andrea D’Aviero, Francesca De Felice, Roberta Grassi, Giuseppe Carlo Iorio, Silvia Longo, Federico Mastroleo, Isacco Desideri, Viola Salvestrini
    La radiologia medica.2024; 129(11): 1720.     CrossRef
  • Selection of induction chemotherapy cycles for stage N3 nasopharyngeal carcinoma based on pre-treatment plasma EBV DNA
    Youliang Weng, Sunqin Cai, Chao Li, Yun Xu, Yuhui Pan, Zongwei Huang, Ying Li, Zijie Wu, Yu Chen, Sufang Qiu
    Scientific Reports.2024;[Epub]     CrossRef
  • A Nomogram for Predicting Recurrence in Stage I Non‐Small Cell Lung Cancer
    Rongrong Bian, Feng Zhao, Bo Peng, Jin Zhang, Qixing Mao, Lin Wang, Qiang Chen
    The Clinical Respiratory Journal.2024;[Epub]     CrossRef
  • Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response
    Yu‐Ting Jiang, Kai‐Hua Chen, Zhong‐Guo Liang, Jie Yang, Song Qu, Ling Li, Xiao‐Dong Zhu
    Cancer Medicine.2023; 12(4): 4010.     CrossRef
  • The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy
    Ji-Jin Yao, Ya-Nan Jin, Yu-Jing Lin, Wang-Jian Zhang, Tia Marks, Ian Ryan, Hong-Yu Zhang, Liang-Ping Xia
    Radiotherapy and Oncology.2023; 178: 109414.     CrossRef
  • Conditional survival nomogram for monitoring real-time survival of young non-metastatic nasopharyngeal cancer survivors
    Jianing Luo, Xiaonan Hu, Xiaofeng Ge
    Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10181.     CrossRef
  • Construction of Prognostic Nomogram in Patients with N3-Stage Nasopharyngeal Carcinoma
    Wenmiao Cao, Xiaoxin Li, Jianqi Yang, Enming Xing, Wenjuan Wu, Yizhi Ge, Buhai Wang
    ORL.2023; 85(4): 195.     CrossRef
  • Regional lymph node density-based nomogram predicts prognosis in nasopharyngeal carcinoma patients without distant metastases
    Jie Ma, Rong Zhao, Yu-Lan Wu, Yang Liu, Guan-Qiao Jin, Dan-Ke Su
    Cancer Imaging.2023;[Epub]     CrossRef
  • Does three cycles of neoadjuvant chemotherapy prior to concurrent chemoradiotherapy provide benefits for all childhood patients with locoregionally advanced nasopharyngeal carcinoma?
    Ya-Nan Jin, Hui-Jiao Cao, Xiao-Hua Gong, Wang-Jian Zhang, Tia Marks, Ji-Jin Yao, Liang-Ping Xia
    Journal of Cancer Research and Clinical Oncology.2022; 148(10): 2569.     CrossRef
  • Development of a web-based prognostic model to quantify the survival benefit of cumulative cisplatin dose during concurrent chemoradiotherapy in childhood nasopharyngeal carcinoma
    Ya-Nan Jin, Qian-Qiong Yang, Zi-Qian Li, Xue-Qing Ou, Wang-Jian Zhang, Tia Marks, Ji-Jin Yao, Liang-Ping Xia
    Radiotherapy and Oncology.2022; 166: 118.     CrossRef
  • A predictive web-based nomogram for the early death of patients with lung adenocarcinoma and bone metastasis: a population-based study
    Zhehong Li, Junqiang Wei, Haiying Cao, Mingze Song, Yafang Zhang, Yu Jin
    Journal of International Medical Research.2021;[Epub]     CrossRef
  • The Role of Pretreatment 18F-FDG PET/CT for Early Prediction of Neoadjuvant Chemotherapy Response in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
    Jijin Yao, Ying Wang, Yujing Lin, Yingying Yang, Jingjing Wan, Xiaohua Gong, Fanwei Zhang, Wangjian Zhang, Tia Marks, Siyang Wang, Hongjun Jin, Hong Shan
    Drug Design, Development and Therapy.2021; Volume 15: 4157.     CrossRef
  • 6,204 View
  • 163 Download
  • 17 Web of Science
  • 17 Crossref
Close layer
Gastrointestinal cancer
Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2–Targeted Agent in the Real-World Setting
Dong-Hoe Koo, Min-Hee Ryu, Mi-Yeon Lee, Heejung Chae, Eo Jin Kim, Mee-Sun Moon, Yoon-Koo Kang
Cancer Res Treat. 2021;53(2):436-444.   Published online October 6, 2020
DOI: https://doi.org/10.4143/crt.2020.725
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to evaluate the survivals of patients with metastatic or recurrent gastric cancer (MRGC) over a period of 16 years and to investigate the recent changes in chemotherapy patterns.
Materials and Methods
A total of 5,384 patients who received chemotherapy for MRGC between 2000 and 2015 were analyzed. The analysis focused on a comparison of the first-line chemotherapy between four periods: 2000–2003 (period 1), 2004–2007 (period 2), 2008–2011 (period 3), and 2012–2015 (period 4).
Results
There were 880 patients (16%) in period 1, 1,573 (29%) in period 2, 1,435 (27%) in period 3, and 1,496 (28%) in period 4. Cytotoxic doublet-based therapy was the most commonly used (78%) first-line chemotherapy, and the combination of trastuzumab and doublet chemotherapy was provided to 288 patients. The OS rates at 12 and 24 months were steadily improved as follows: 39.2% and 14.6% in period 1, 43.5% and 17.6% in period 2, 50.3% and 20.6% in period 3, and 51.7% and 24.1% in period 4, respectively (p < 0.001). Among the patients who received the doublet-based chemotherapy, the median OS of those who received trastuzumab was 18.0 months (95% CI, 15.5–20.6), while that of those who received other doublet therapies was 11.2 months (95% CI, 10.8–11.6).
Conclusion
The OS was improved over time with advancements in chemotherapy, particularly the introduction of the anti-HER2–targeted agent, which contributed to the increase in the number of long-term survivors and established the superiority of OS for the treatment of MRGC.

Citations

Citations to this article as recorded by  
  • Treatment Modalities and Survival Outcomes in Gastric Cancer: Insights From Najran, Saudi Arabia
    Ahmed M Badheeb, Ibrahim A Alyami, Ahlam Y Alyami, Mohammed Alyami, Mugahed Al Walani, Samer Alkarak, Abdelaziz A Aman, Fahad M Albaiji, Ali G Al Masad, Abdullah S Alyami, Islam A Seada, Abdullah Abu Bakar
    Cureus.2025;[Epub]     CrossRef
  • Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China
    Jingdong Zhang, Guangyu Wang, Xianhe Xie, Wensheng Pan, Qian Dong, Nianhai Zhang, Jie Dong, Li Zhou, Chan Zhou, Jinnan Li, Grace Segall, Yanqiao Zhang
    Future Oncology.2025; 21(10): 1179.     CrossRef
  • Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair
    Young-Gyu Park, Hyung-Don Kim, Jaewon Hyung, Young Soo Park, Min-Hee Ryu
    Gastric Cancer.2024; 27(4): 840.     CrossRef
  • Varlitinib and Paclitaxel for EGFR/HER2 Co-expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13)
    Dong-Hoe Koo, Minkyu Jung, Yeul Hong Kim, Hei-Cheul Jeung, Dae Young Zang, Woo Kyun Bae, Hyunki Kim, Hyo Song Kim, Choong-kun Lee, Woo Sun Kwon, Hyun Cheol Chung, Sun Young Rha
    Cancer Research and Treatment.2024; 56(4): 1136.     CrossRef
  • Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination
    Sun Young Rha, Hyun Cheol Chung
    Journal of Gastric Cancer.2023;[Epub]     CrossRef
  • Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab
    Kyunghye Bang, Jaekyung Cheon, Young Soo Park, Hyung-Don Kim, Min-Hee Ryu, Yangsoon Park, Meesun Moon, Hyungeun Lee, Yoon-Koo Kang
    Gastric Cancer.2022; 25(4): 794.     CrossRef
  • Clinicopathological features and CT findings of papillary gastric adenocarcinoma
    Mengying Xu, Song Liu, Xiangmei Qiao, Lin Li, Changfeng Ji, Zhengyang Zhou
    Abdominal Radiology.2022; 47(11): 3698.     CrossRef
  • New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy
    Dong-Hoe Koo, Min-Hee Ryu, Mi-Yeon Lee, Mee-Sun Moon, Yoon-Koo Kang
    World Journal of Gastroenterology.2021; 27(48): 8357.     CrossRef
  • 6,673 View
  • 165 Download
  • 8 Crossref
Close layer
Gynecologic cancer
Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea
Se Ik Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song
Cancer Res Treat. 2020;52(4):1229-1241.   Published online July 27, 2020
DOI: https://doi.org/10.4143/crt.2020.557
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to present a single institutional experience with BRCA1/2 gene tests and the effects of pathogenic mutations in epithelial peritoneal, ovarian, and fallopian tube cancer (POFTC) on survival outcomes.
Materials and Methods
We identified patients with epithelial POFTCs who underwent BRCA1/2 gene testing by either germline or somatic methods between March 2007 and March 2020. Based on the BRCA1/2 test results, patients were divided into BRCA mutation and wild-type groups, followed by comparisons of clinicopathologic characteristics and survival outcomes after primary treatment.
Results
The annual number of POFTC patients who received BRCA1/2 gene tests increased gradually. In total, 511 patients were included and BRCA1/2 mutations were observed in 143 (28.0%). Among 57 patients who received both germline and somatic tests, three (5.3%) showed discordant results from the two tests. Overall, no differences in progression-free survival (PFS; p=0.467) and overall survival (p=0.641) were observed between the BRCA mutation and wild-type groups; however, multivariate analyses identified BRCA1/2 mutation as an independent favorable prognostic factor for PFS (adjusted hazard ratio [aHR], 0.765; 95% confidence interval [CI], 0.593 to 0.987; p=0.040). In 389 patients with International Federation of Gynecology and Obstetrics stage III-IV, different results were shown depending on primary treatment strategy: while BRCA1/2 mutation significantly improved PFS in the subgroup of neoadjuvant chemotherapy (aHR, 0.619; 95% CI, 0.385 to 0.995; p=0.048), it did not affect patient PFS in the subgroup of primary debulking surgery (aHR, 0.759; 95% CI, 0.530 to 1.089; p=0.135).
Conclusion
BRCA1/2 mutations are frequently observed in patients with epithelial POFTCs, and such patients showed better PFS than did those harboring wild-type BRCA1/2.

Citations

Citations to this article as recorded by  
  • Overview of Molecular Diagnostics in Irish Clinical Oncology
    Tyler Medina, Seán O. Hynes, Maeve Lowery, Paddy Gillespie, Walter Kolch, Cathal Seoighe
    HRB Open Research.2024; 7: 16.     CrossRef
  • Trends in the Incidence and Survival Rates of Primary Ovarian Clear Cell Carcinoma Compared to Ovarian Serous Carcinoma in Korea
    Se Ik Kim, Hyeong In Ha, Kyung Jin Eoh, Jiwon Lim, Young-Joo Won, Myong Cheol Lim
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Characteristics of homologous recombination repair pathway genes mutation in ovarian cancers
    Zongbi Yi, Min Chen, Shaoxing Sun, Chunxu Yang, Zijie Mei, Hui Yang, Qingming Xiang, Hui Qiu
    Cancer Innovation.2022; 1(3): 220.     CrossRef
  • 8,053 View
  • 214 Download
  • 12 Web of Science
  • 3 Crossref
Close layer
Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer
Young Shin Chung, Hyun-Soo Kim, Jung-Yun Lee, Won Jun Kang, Eun Ji Nam, Sunghoon Kim, Sang Wun Kim, Young Tae Kim
Cancer Res Treat. 2020;52(4):1211-1218.   Published online April 28, 2020
DOI: https://doi.org/10.4143/crt.2019.506
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The aim of this study was to evaluate the ability of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) after one cycle of neoadjuvant chemotherapy (NAC) to predict chemotherapy response before interval debulking surgery (IDS) in advanced-stage ovarian cancer patients.
Materials and Methods
Forty consecutive patients underwent 18F-FDG-PET/CT at baseline and after one cycle of NAC. Metabolic responses were assessed by quantitative decrease in the maximum standardized uptake value (SUVmax) with PET/CT. Decreases in SUVmax were compared with cancer antigen 125 (CA-125) level before IDS, response rate by Response Evaluation Criteria in Solid Tumors criteria before IDS, residual tumor at IDS, and I chemotherapy response score (CRS) at IDS.
Results
A 40% cut-off for the decrease in SUVmax provided the best performance to predict CRS 3 (compete or near-complete pathologic response), with sensitivity, specificity, and accuracy of 81.8%, 72.4%, and 72.4%, respectively. According to this 40% cut-off, there were 17 (42.5%) metabolic responders (≥ 40%) and 23 (57.5%) metabolic non-responders (< 40%). Metabolic responders had higher rate of CRS 3 (52.9% vs. 8.7%, p=0.003), CA-125 normalization (< 35 U/mL) before IDS (76.5% vs. 39.1%, p=0.019), and no residual tumor at IDS (70.6% vs. 31.8%, p=0.025) compared with metabolic non-responders. There were significant associations with progression-free survival (p=0.021) between metabolic responders and non-responders, but not overall survival (p=0.335).
Conclusion
Early assessment with 18F-FDG-PET/CT after one cycle of NAC can be useful to predic response to chemotherapy before IDS in patients with advanced-stage ovarian cancer.

Citations

Citations to this article as recorded by  
  • The Evaluation Value of CT in the Efficacy of Neoadjuvant Chemotherapy in Ovarian Cancer Patients
    Daying Mou, Shengyan Xie, Pingyuan Li, Mohammad Farukh Hashmi
    Contrast Media & Molecular Imaging.2022;[Epub]     CrossRef
  • Radiomics Analysis of PET and CT Components of 18F-FDG PET/CT Imaging for Prediction of Progression-Free Survival in Advanced High-Grade Serous Ovarian Cancer
    Xihai Wang, Zaiming Lu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • 8,592 View
  • 136 Download
  • 7 Web of Science
  • 2 Crossref
Close layer
Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma
Miao Xue, Yanqin Wu, Wenzhe Fan, Jian Guo, Jialiang Wei, Hongyu Wang, Jizhou Tan, Yu Wang, Wang Yao, Yue Zhao, Jiaping Li
Cancer Res Treat. 2020;52(3):925-937.   Published online March 30, 2020
DOI: https://doi.org/10.4143/crt.2019.533
AbstractAbstract PDFPubReaderePub
Purpose
This study aimed to investigate the clinicopathologic features and mutational landscape of patients with hepatitis B virus (HBV)–related advanced hepatocellular carcinomas (HCC) undergoing transcatheter arterial chemoembolization (TACE).
Materials and Methods
From January 2017 to December 2018, 38 patients newly diagnosed with HBV-related advanced HCC were enrolled in the final analysis. Their pathological tissues and corresponding blood samples before TACE treatment were collected for whole-exome sequencing. Response to TACE was evaluated at 1-3 months after two consecutive use of TACE. Predictive factors were analyzed by univariate and multivariate analyses in a bivariate Logistic regression model. Enrichment of related pathways of all driver genes were acquired using the gene set enrichment analysis (GSEA).
Results
Among 38 patients, 23 (60.5%) exhibited TACE failure/refractoriness. Patients with TACE failure/refractoriness showed higher frequency of TP53 mutation than their counterparts (p=0.020). Univariate and multivariate analyses showed that only vascular invasion and TP53 mutation were significantly correlated with TACE failure/refractoriness in HBV-related advanced HCC. Of the 16 patients without vascular invasion, eight (50.0%) had TP53 mutations, and TP53 mutation was associated with TACE failure/refractoriness (p=0.041). Moreover, GSEA showed that mitogen-activated protein kinase and apoptosis pathways induced by TP53 mutation were possibly associated with TACE failure/refractoriness.
Conclusion
Our study suggested that TP53 mutation was independently related with TACE efficacy, which may work via mitogen-activated protein kinase and apoptosis pathways. These findings may provide evidence to help distinguish patients who will particularly benefit from TACE from those who require more personalized therapeutic regimens and rigorous surveillance in HBV-related advanced HCC.

Citations

Citations to this article as recorded by  
  • Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study
    Qi Fan, Pengcheng Wei, Delin Ma, Qian Cheng, Jie Gao, Jiye Zhu, Zhao Li
    Surgery Open Science.2025; 23: 16.     CrossRef
  • TP53 Mutation Predicts Worse Survival and Earlier Local Progression in Patients with Hepatocellular Carcinoma Treated with Transarterial Embolization
    Ken Zhao, Anita Karimi, Luke Kelly, Elena Petre, Brett Marinelli, Erica S. Alexander, Vlasios S. Sotirchos, Joseph P. Erinjeri, Anne Covey, Constantinos T. Sofocleous, James J. Harding, William Jarnagin, Carlie Sigel, Efsevia Vakiani, Etay Ziv, Hooman Yar
    Current Oncology.2025; 32(1): 51.     CrossRef
  • Clinical Therapy: HAIC Combined with Tyrosine Kinase Inhibitors and Programmed Cell Death Protein-1 Inhibitors versus HAIC Alone for Unresectable Hepatocellular Carcinoma
    Baokun Liu, Lujun Shen, Wen Liu, Zhiyong Zhang, Jieqiong Lei, Zhengguo Li, Qinquan Tan, Hengfei Huang, Xingdong Wang, Weijun Fan
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 1557.     CrossRef
  • Enhanced interactions within microenvironment accelerates dismal prognosis in HBV-related HCC after TACE
    Libo Wang, Jiahui Cao, Zaoqu Liu, Shitao Wu, Yin Liu, Ruopeng Liang, Rongtao Zhu, Weijie Wang, Jian Li, Yuling Sun
    Hepatology Communications.2024;[Epub]     CrossRef
  • Development and validation of survival prediction models for patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus tyrosine kinase inhibitors
    Kun Huang, Haikuan Liu, Yanqin Wu, Wenzhe Fan, Yue Zhao, Miao Xue, Yiyang Tang, Shi-Ting Feng, Jiaping Li
    La radiologia medica.2024; 129(11): 1597.     CrossRef
  • Identification of BRD7 by whole-exome sequencing as a predictor for intermediate-stage hepatocellular carcinoma in patients undergoing TACE
    Kun Huang, Yanqin Wu, Wenzhe Fan, Yue Zhao, Miao Xue, Haikuan Liu, Yiyang Tang, Jiaping Li
    Journal of Cancer Research and Clinical Oncology.2023; 149(13): 11247.     CrossRef
  • Prediction model of no-response before the first transarterial chemoembolization for hepatocellular carcinoma: TACF score
    Jia-Wei Zhong, Dan-Dan Nie, Ji-Lan Huang, Rong-Guang Luo, Qing-He Cheng, Qiao-Ting Du, Gui-Hai Guo, Liang-Liang Bai, Xue-Yun Guo, Yan Chen, Si-Hai Chen
    Discover Oncology.2023;[Epub]     CrossRef
  • Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems
    Jose J.G. Marin, Marta R. Romero, Elisa Herraez, Maitane Asensio, Sara Ortiz-Rivero, Anabel Sanchez-Martin, Luca Fabris, Oscar Briz
    Seminars in Liver Disease.2022; 42(01): 087.     CrossRef
  • Non-Apoptotic Programmed Cell Death-Related Gene Signature Correlates With Stemness and Immune Status and Predicts the Responsiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma
    Guixiong Zhang, Wenzhe Fan, Hongyu Wang, Jie Wen, Jizhou Tan, Miao Xue, Jiaping Li
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • Plasma arginase-1 as a predictive marker for early transarterial chemoembolization refractoriness in unresectable hepatocellular carcinoma
    Wei-Li Xia, Shi-Jun Xu, Yuan Guo, Xiao-Hui Zhao, Hong-Tao Hu, Yan Zhao, Quan-Jun Yao, Lin Zheng, Dong-Yang Zhang, Chen-Yang Guo, Wei-Jun Fan, Hai-Liang Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Useful genes for predicting the efficacy of transarterial chemoembolization in hepatocellular carcinoma
    Yuan Guo, Hongtao Hu, Shijun Xu, Weili Xia, Hailiang Li
    Journal of Cancer Research and Therapeutics.2022; 18(7): 1860.     CrossRef
  • Development and Validation of a Predictive Model for Early Refractoriness of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma
    Tian-Cheng Wang, Tian-Zhi An, Jun-Xiang Li, Zi-Shu Zhang, Yu-Dong Xiao
    Frontiers in Molecular Biosciences.2021;[Epub]     CrossRef
  • Transcatheter arterial chemoembolization followed by surgical resection for hepatocellular carcinoma: a focus on its controversies and screening of patients most likely to benefit
    Zhan-Qi Wei, Yue-Wei Zhang
    Chinese Medical Journal.2021; 134(19): 2275.     CrossRef
  • Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma
    Young Chang, Soung Won Jeong, Jae Young Jang, Yong Jae Kim
    International Journal of Molecular Sciences.2020; 21(21): 8165.     CrossRef
  • 8,754 View
  • 150 Download
  • 15 Web of Science
  • 14 Crossref
Close layer
Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in East Asia
Jin Kyung Suh, Yi-Jin Gao, Jing-Yan Tang, Shiann-Tarng Jou, Dong-Tsamn Lin, Yoshiyuki Takahashi, Seiji Kojima, Ling Jin, Yonghong Zhang, Jong Jin Seo
Cancer Res Treat. 2020;52(2):359-368.   Published online July 29, 2019
DOI: https://doi.org/10.4143/crt.2019.219
AbstractAbstract PDFPubReaderePub
Purpose
The presentations and geographic incidence of pediatric non-Hodgkin lymphoma (NHL) differ from those of adults. This study delineated the characteristics and outcomes of pediatric NHL in East Asia.
Materials and Methods
Medical records of 749 pediatric patients with NHL treated at participating institutions in mainland China, Japan, Korea, and Taiwan from January 2008 to December 2013 were reviewed. Demographic and clinical features, survival outcomes, and putative prognostic factors were analyzed.
Results
Five hundred thirty patients (71%) were male. The most common pathologic subtypes were Burkitt lymphoma (BL) (36%). Six hundred seven patients (81%) had advanced diseases at diagnosis. The 5-year overall survival and event-free survival (EFS) rates were 89% and 84%. The 5-year EFS rates of BL, lymphoblastic lymphoma, and diffuse large B-cell lymphoma were 88%, 88%, and 89%, and those of anaplastic large cell lymphoma (ALCL) and peripheral T-cell lymphoma (PTCL) were 71% and 56% (p < 0.001). Central nervous system involvement, high lactate dehydrogenase level (> 250 IU/mL), and advanced disease at diagnosis (≥ stage III) were associated with poor outcomes (p < 0.05). ALCL and PTCL relapsed more frequently than other pathologic subtypes (p < 0.001).
Conclusion
In East Asia, PTCL was more frequent than in Western countries, and bone marrow involvement did not affect treatment outcome. This international study should motivate future collaborative study on NHL in East Asia.

Citations

Citations to this article as recorded by  
  • Evaluation of NHL subtypes, staging, and prognostic factors: A single-centric retrospective cohort study
    Ulfat A. Wani, Umeek Jeelani, Sheikh A. Aziz, Bashrat Ara Wani, Gul M. Bhat, Kaneez Fatima, Shaheen N. Lone, Asifa Andleeb
    Journal of Cancer Research and Therapeutics.2025; 21(1): 34.     CrossRef
  • Hemoglobinopathies, merozoite surface protein-2 gene polymorphisms, and acquisition of Epstein Barr virus among infants in Western Kenya
    Perez K. Olewe, Shehu Shagari Awandu, Elly O. Munde, Samuel B. Anyona, Evans Raballah, Asito S. Amolo, Sidney Ogola, Erick Ndenga, Clinton O. Onyango, Rosemary Rochford, Douglas J. Perkins, Collins Ouma
    BMC Cancer.2023;[Epub]     CrossRef
  • iTRAQ-Based Proteomic Analysis Reveals Potential Serum Biomarkers for Pediatric Non-Hodgkin’s Lymphoma
    Runhong Yu, Linna Cheng, Shiwei Yang, Yufeng Liu, Zunmin Zhu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • 9,249 View
  • 396 Download
  • 4 Web of Science
  • 3 Crossref
Close layer
Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer
Se Ik Kim, Minsun Song, Suhyun Hwangbo, Sungyoung Lee, Untack Cho, Ju-Hyun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Dae-Shik Suh, Taesung Park, Yong-Sang Song
Cancer Res Treat. 2019;51(3):1144-1155.   Published online November 20, 2018
DOI: https://doi.org/10.4143/crt.2018.508
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Discovery of models predicting the exact prognosis of epithelial ovarian cancer (EOC) is necessary as the first step of implementation of individualized treatment. This study aimed to develop nomograms predicting treatment response and prognosis in EOC.
Materials and Methods
We comprehensively reviewed medical records of 866 patients diagnosed with and treated for EOC at two tertiary institutional hospitals between 2007 and 2016. Patients’ clinico-pathologic characteristics, details of primary treatment, intra-operative surgical findings, and survival outcomes were collected. To construct predictive nomograms for platinum sensitivity, 3-year progression-free survival (PFS), and 5-year overall survival (OS), we performed stepwise variable selection by measuring the area under the receiver operating characteristic curve (AUC) with leave-one-out cross-validation. For model validation, 10-fold cross-validation was applied.
Results
The median length of observation was 42.4 months (interquartile range, 25.7 to 69.9 months), during which 441 patients (50.9%) experienced disease recurrence. The median value of PFS was 32.6 months and 3-year PFS rate was 47.8% while 5-year OS rate was 68.4%. The AUCs of the newly developed nomograms predicting platinum sensitivity, 3-year PFS, and 5-year OS were 0.758, 0.841, and 0.805, respectively. We also developed predictive nomograms confined to the patients who underwent primary debulking surgery. The AUCs for platinum sensitivity, 3-year PFS, and 5-year OS were 0.713, 0.839, and 0.803, respectively.
Conclusion
We successfully developed nomograms predicting treatment response and prognosis of patients with EOC. These nomograms are expected to be useful in clinical practice and designing clinical trials.

Citations

Citations to this article as recorded by  
  • Comprehensive analyses of mitophagy-related genes and mitophagy-related lncRNAs for patients with ovarian cancer
    Jianfeng Zheng, Shan Jiang, Xuefen Lin, Huihui Wang, Li Liu, Xintong Cai, Yang Sun
    BMC Women's Health.2024;[Epub]     CrossRef
  • Peripheral and tumor‐infiltrating immune cells are correlated with patient outcomes in ovarian cancer
    Weiwei Zhang, Yawen Ling, Zhidong Li, Xingchen Peng, Yazhou Ren
    Cancer Medicine.2023; 12(8): 10045.     CrossRef
  • Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods
    Seung Mi Lee, Suhyun Hwangbo, Errol R. Norwitz, Ja Nam Koo, Ig Hwan Oh, Eun Saem Choi, Young Mi Jung, Sun Min Kim, Byoung Jae Kim, Sang Youn Kim, Gyoung Min Kim, Won Kim, Sae Kyung Joo, Sue Shin, Chan-Wook Park, Taesung Park, Joong Shin Park
    Clinical and Molecular Hepatology.2022; 28(1): 105.     CrossRef
  • Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives
    Stanislas Quesada, Michel Fabbro, Jérôme Solassol
    Cancers.2022; 14(4): 1098.     CrossRef
  • Construction and validation of a transcription factors-based prognostic signature for ovarian cancer
    Qingyuan Cheng, Liman Li, Mingxia Yu
    Journal of Ovarian Research.2022;[Epub]     CrossRef
  • Predicting preterm birth through vaginal microbiota, cervical length, and WBC using a machine learning model
    Sunwha Park, Jeongsup Moon, Nayeon Kang, Young-Han Kim, Young-Ah You, Eunjin Kwon, AbuZar Ansari, Young Min Hur, Taesung Park, Young Ju Kim
    Frontiers in Microbiology.2022;[Epub]     CrossRef
  • Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma
    Jiayi Li, Dongyan Cao
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Recent Advances and Future Directions of Diagnostic and Prognostic Prediction Models in Ovarian Cancer
    Judan Zeng, Wenjiao Cao, Lihua Wang
    Journal of Shanghai Jiaotong University (Science).2021; 26(1): 10.     CrossRef
  • Sphingolipids as multifaceted mediators in ovarian cancer
    MelissaR Pitman, Martin K. Oehler, Stuart M. Pitson
    Cellular Signalling.2021; 81: 109949.     CrossRef
  • Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial–mesenchymal transition
    Jiani Yang, Jun Ma, Yue Jin, Shanshan Cheng, Shan Huang, Nan Zhang, Yu Wang
    Scientific Reports.2021;[Epub]     CrossRef
  • Prediction Models for the Clinical Severity of Patients With COVID-19 in Korea: Retrospective Multicenter Cohort Study
    Bumjo Oh, Suhyun Hwangbo, Taeyeong Jung, Kyungha Min, Chanhee Lee, Catherine Apio, Hyejin Lee, Seungyeoun Lee, Min Kyong Moon, Shin-Woo Kim, Taesung Park
    Journal of Medical Internet Research.2021; 23(4): e25852.     CrossRef
  • Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
    Suhyun Hwangbo, Se Ik Kim, Ju-Hyun Kim, Kyung Jin Eoh, Chanhee Lee, Young Tae Kim, Dae-Shik Suh, Taesung Park, Yong Sang Song
    Cancers.2021; 13(8): 1875.     CrossRef
  • M2 Macrophage-Based Prognostic Nomogram for Gastric Cancer After Surgical Resection
    Jianwen Hu, Yongchen Ma, Ju Ma, Yanpeng Yang, Yingze Ning, Jing Zhu, Pengyuan Wang, Guowei Chen, Yucun Liu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Prognosis for intrahepatic cholangiocarcinoma patients treated with postoperative adjuvant transcatheter hepatic artery chemoembolization
    Ji-Bin Liu, Kai-Jian Chu, Chang-Chun Ling, Ting-Miao Wu, Hui-Min Wang, Yi Shi, Zhi-Zhen Li, Jing-Han Wang, Zhi-Jun Wu, Xiao-Qing Jiang, Gao-Ren Wang, Yu-Shui Ma, Da Fu
    Current Problems in Cancer.2020; 44(6): 100612.     CrossRef
  • Can we predict who lives long with ovarian cancer?
    Michael A. Bookman
    Cancer.2019; 125(S24): 4578.     CrossRef
  • 10,250 View
  • 266 Download
  • 16 Web of Science
  • 15 Crossref
Close layer
The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era
Ya-Nan Jin, Wang-Jian Zhang, Xiu-Yu Cai, Mei-Su Li, Wayne R. Lawrence, Si-Yang Wang, Dong-Mei Mai, Yu-Yun Du, Dong-Hua Luo, Hao-Yuan Mo
Cancer Res Treat. 2019;51(1):34-42.   Published online February 6, 2018
DOI: https://doi.org/10.4143/crt.2017.551
AbstractAbstract PDFPubReaderePub
Purpose
We aim to examine nasopharyngeal carcinoma (NPC) characteristics and survival outcomes in patients aged 70 years and older in the intensity-modulated radiotherapy (IMRT) era.
Methods
and Materials From 2006 to 2013, 126 non-metastatic NPC patients aged ≥ 70 years who were treated with IMRT +/‒ chemotherapy were included. Adult Comorbidity Evaluation 27 (ACE-27) was used to measure patient comorbidities. The overall survival (OS) and cancer-specific survival (CSS)were calculatedwith the Kaplan-Meier method, and differenceswere compared using the log-rank test. The Cox proportional hazards model was used to carry out multivariate analyses.
Results
For the entire group, only two patients (1.6%) presented stage I disease, and up to 84.1% patients had stage III-IVB disease. All patients had a comorbidity score of 0 in 24 (19.0%), 1 in 45 (35.7%), 2 in 42 (33.3%), and 3 in 15 (11.9%) patients. The main acute grade during radiotherapy was 3-4 adverse events consisting of mucositis (25.4%), bone marrow suppression (16.7%), and dermatitis (8.7%). After treatment, four patients (3.2%) developed temporal lobe injury. Five-year CSS and OS rates were 67.3% (95% confidence interval [CI], 58.6% to 77.4%) and 54.0% (95% CI, 45.6% to 63.9%), respectively. Five-year OS was significantly higher for ACE-27 score 0-1 than ACE-27 score 2-3 (72.9% and 39.9%, respectively; p < 0.001). Multivariate analyses showed ACE-27 score 0-1 was significantly associated with superior OS (hazard ratio [HR], 3.02; 95% CI, 1.64 to 5.55; p < 0.001). In addition, the rate of OS was higher for stage I-III than that of stage IV, with borderline significance (HR, 1.67; 95% CI, 0.99 to 2.82; p=0.053). But no significant advantage was observed in OS when chemotherapy was used (p > 0.05).
Conclusion
Our findings suggest IMRT +/– chemotherapy has a manageable toxicity and provides an acceptable survival in patients aged ≥ 70 years with NPC. ACE-27 score was significantly associated with survival outcomes in this group population.

Citations

Citations to this article as recorded by  
  • Neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in elderly patients with stage III‐IVa nasopharyngeal carcinoma: A real‐world study based on medical comorbidities
    Ya‐Nan Jin, Zhi‐Wen Xiao, Wei Yao, Jing Yu, Wang‐Jian Zhang, Tia Marks, Hong‐Yu Zhang, Ji‐Jin Yao, Liang‐Ping Xia
    Head & Neck.2024; 46(8): 2020.     CrossRef
  • Therapeutic Approaches to Increase the Survival Rate of Cancer Patients in the Younger and Older Population
    Tharrun Paul, Kanagaraj Palaniyandi, Dhanavathy Gnanasampanthapandian
    Current Aging Science.2024; 17(1): 16.     CrossRef
  • Lobaplatin-based concurrent chemoradiotherapy in elderly nasopharyngeal carcinoma
    Yi-Feng Yu, Ping Zhou, Rui Zhou, Qin Lin, San-Gang Wu
    Annals of Medicine.2024;[Epub]     CrossRef
  • Prognostic Analysis of Nonmetastatic Nasopharyngeal Carcinoma in Older Patients Undergoing Intensity‐Modulated Radiotherapy
    Shuangyue Wang, Heqing Huang, Fengqiao Huang, Haiyan Wu, Zhiru Li, Ziyan Zhou, Min Kang, Dawei Cui
    International Journal of Clinical Practice.2024;[Epub]     CrossRef
  • Elderly nasopharyngeal carcinoma patients (aged ≥70 years): Survival and treatment strategies
    Gang Yang, Jingjing Huang, Ji Sun, Li Wang
    Cancer Medicine.2023; 12(19): 19523.     CrossRef
  • Management of Nasopharyngeal Carcinoma in Elderly Patients
    Wing Lok Chan, James Chung Hang Chow, Zhi-yuan Xu, Jishi Li, Wing Tung Gobby Kwong, Wai Tong Ng, Anne W. M. Lee
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Institutionally Validated Nomogram Predicting Prognosis for Older Patients with Nonmetastatic Nasopharyngeal Carcinoma
    Chao Yan, Ziwei Tu, Zixian Zhang, Xi Ouyang, Dou Li, Shiyi Peng, Jun Zhong
    Future Oncology.2022; 18(15): 1829.     CrossRef
  • The Interplay between Age and Viral Status in EBV-Related Nasopharyngeal and HPV-Related Oropharyngeal Carcinoma Patients
    Stefano Cavalieri, Paolo Bossi, Gabriele Infante, Rosalba Miceli, Nicola Alessandro Iacovelli, Eliana Ivaldi, Laura Deborah Locati, Cristiana Bergamini, Carlo Resteghini, Imperia Nuzzolese, Salvatore Alfieri, Elena Colombo, Rossana Ingargiola, Marzia Fran
    Cancers.2022; 14(24): 6170.     CrossRef
  • Clinical characteristics and prognosis of elderly nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy
    Yingchen Lyu, Mengshan Ni, Ruiping Zhai, Fangfang Kong, Chengrun Du, Chaosu Hu, Hongmei Ying
    European Archives of Oto-Rhino-Laryngology.2021; 278(7): 2549.     CrossRef
  • Development of a Comorbidity-Based Nomogram to Predict Survival After Salvage Reirradiation of Locally Recurrent Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era
    Run-Da Huang, Zhuang Sun, Xiao-Hui Wang, Yun-Ming Tian, Ying-Lin Peng, Jing-Yun Wang, Wei-Wei Xiao, Chun-Yan Chen, Xiao-Wu Deng, Fei Han
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area
    Ji-Jin Yao, Li Lin, Tian-Sheng Gao, Wang-Jian Zhang, Wayne R. Lawrence, Jun Ma, Ying Sun
    Cancer Research and Treatment.2021; 53(3): 657.     CrossRef
  • Development of a Nomogram Model for Treatment of Elderly Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
    Jia Kou, Lu-Lu Zhang, Xing-Li Yang, Dan-Wan Wen, Guan-Qun Zhou, Chen-Fei Wu, Si-Si Xu, Wei-Hong Zheng, Zhen-Yu Qi, Ying Sun, Li Lin
    Journal of Personalized Medicine.2021; 11(11): 1065.     CrossRef
  • MicroRNA-424-5p inhibits the proliferation, migration, and invasion of nasopharyngeal carcinoma cells by decreasing AKT3 expression
    Chong Zhao, Feng Zhao, Huiying Chen, Yuehua Liu, Jiping Su
    Brazilian Journal of Medical and Biological Research.2020;[Epub]     CrossRef

  • Acute Toxicities and Prognosis of Elderly Patients with Nasopharyngeal Carcinoma After Intensity-Modulated Radiotherapy: Prediction with Nomogram


    Yu Liang, Kai-hua Chen, Jie Yang, Jing Zhang, Ru-rong Peng, Song Qu, Ling Li, Xiao-dong Zhu
    Cancer Management and Research.2020; Volume 12: 8821.     CrossRef
  • Genome-Wide Association Study of Susceptibility Loci for Radiation-Induced Brain Injury
    Tong-Min Wang, Guo-Ping Shen, Ming-Yuan Chen, Jiang-Bo Zhang, Ying Sun, Jing He, Wen-Qiong Xue, Xi-Zhao Li, Shao-Yi Huang, Xiao-Hui Zheng, Shao-Dan Zhang, Ye-Zhu Hu, Hai-De Qin, Jin-Xin Bei, Jun Ma, Jianbing Mu, Yin Yao Shugart, Wei-Hua Jia
    JNCI: Journal of the National Cancer Institute.2018;[Epub]     CrossRef
  • 16,995 View
  • 326 Download
  • 16 Web of Science
  • 15 Crossref
Close layer
The Effect of Hospital Case Volume on Clinical Outcomes in Patients with Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Analysis (KROG-1106)
Boram Ha, Kwan Ho Cho, Sung Ho Moon, Chang-Geol Lee, Ki Chang Keum, Yeon-Sil Kim, Hong-Gyun Wu, Jin Ho Kim, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Jong Hoon Lee, Sung Hwan Kim, Won Taek Kim, Young-Taek Oh, Min Kyu Kang, Jin Hee Kim, Ji-Yoon Kim, Moon-June Cho, Chul Seoung Kay, Jin Hwa Choi
Cancer Res Treat. 2019;51(1):12-23.   Published online February 5, 2018
DOI: https://doi.org/10.4143/crt.2017.273
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the effect of hospital case volume on clinical outcomes in patients with nasopharyngeal carcinoma (NPC).
Materials and Methods
Data on 1,073 patients with cT1-4N0-3M0 NPC were collected from a multi-institutional retrospective database (KROG 11-06). All patients received definitive radiotherapy (RT) either with three-dimensional-conformal RT (3D-CRT) (n=576) or intensity-modulated RT (IMRT) (n=497). The patients were divided into two groups treated at high volume institution (HVI) (n=750) and low volume institution (LVI) (n=323), defined as patient volume ≥ 10 (median, 13; range, 10 to 18) and < 10 patients per year (median, 3; range, 2 to 6), respectively. Endpoints were overall survival (OS) and loco-regional progression-free survival (LRPFS).
Results
At a median follow-up of 56.7 months, the outcomes were significantly better in those treated at HVI than at LVI. For the 614 patients of propensity score-matched cohort, 5-year OS and LRPFS were consistently higher in the HVI group than in the LVI group (OS: 78.4% vs. 62.7%, p < 0.001; LRPFS: 86.2% vs. 65.8%, p < 0.001, respectively). According to RT modality, significant difference in 5-year OS was observed in patients receiving 3D-CRT (78.7% for HVI vs. 58.9% for LVI, p < 0.001) and not in those receiving IMRT (77.3% for HVI vs. 75.5% for LVI, p=0.170).
Conclusion
A significant relationship was observed between HVI and LVI for the clinical outcomes of patients with NPC. However, the difference in outcome becomes insignificant in the IMRT era, probably due to the standardization of practice by education.

Citations

Citations to this article as recorded by  
  • Accumulated Dose Deviation of Rotational and Residual Setup Errors on Nasopharyngeal Carcinoma Using MIM Treated by Helical Tomotherapy
    Wenyan Yao, Jiang Hu, Peixun Xu, Mengxue He, Yongwen Fang, Mingzhi Liu, Zongtai Li, Huilang He, Hui Liu, Wenzhao Sun, Senkui Xu
    Technology in Cancer Research & Treatment.2023;[Epub]     CrossRef
  • Systematic Review and Meta-analysis of the Association Between Radiation Therapy Treatment Volume and Patient Outcomes
    Jerry Ye Aung Kyaw, Alice Rendall, Erin F. Gillespie, Tom Roques, Laurence Court, Yolande Lievens, Alison C. Tree, Chris Frampton, Ajay Aggarwal
    International Journal of Radiation Oncology*Biology*Physics.2023; 117(5): 1063.     CrossRef
  • The Influence of Hospital Volume on the Outcomes of Nasopharyngeal, Sinonasal, and Skull-Base Tumors: A Systematic Review of the Literature
    Stephanie Flukes, Rahul K. Sharma, Shivangi Lohia, Marc A. Cohen
    Journal of Neurological Surgery Part B: Skull Base.2022; 83(03): 270.     CrossRef
  • A Comprehensive Analysis of Treatment Management and Survival Outcomes in Nasopharyngeal Carcinoma
    Khodayar Goshtasbi, Brandon M. Lehrich, Jack L. Birkenbeuel, Arash Abiri, Jeremy P. Harris, Edward C. Kuan
    Otolaryngology–Head and Neck Surgery.2021; 165(1): 93.     CrossRef
  • Hospital volume and physician volume in association with survival in patients with nasopharyngeal cancer after radiation therapy
    Tzu-Yu Lai, Chiu-Mei Yeh, Yu-Wen Hu, Chia-Jen Liu
    Radiotherapy and Oncology.2020; 151: 190.     CrossRef
  • 10,342 View
  • 215 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
Survival and Functional Outcome after Treatment for Primary Base of Tongue Cancer: A Comparison of Definitive Chemoradiotherapy versus Surgery Followed by Adjuvant Radiotherapy
Sangjoon Park, Yeona Cho, Jeongshim Lee, Yoon Woo Koh, Se-Heon Kim, Eun Chang Choi, Hye Ryun Kim, Ki Chang Keum, Kyung Ran Park, Chang Geol Lee
Cancer Res Treat. 2018;50(4):1214-1225.   Published online December 26, 2017
DOI: https://doi.org/10.4143/crt.2017.498
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to compare the clinical and functional outcomes in patients with primary base of tongue (BOT) cancer who received definitive radiotherapy (RT) or surgery followed by radiotherapy (SRT).
Materials and Methods
Between January 2002 andDecember 2016, 102 patientswith stage I-IVB primary BOT cancer underwent either definitive RT (n=46) or SRT (n=56), and treatment outcomeswere compared between two groups. The expression of p16 was also analyzed.
Results
The RT group had more patients with advanced T stage (T3-4) disease (58.7% vs. 35.7%, p=0.021) and who received chemotherapy (91.3% vs. 37.5%, p < 0.001) than the SRT group. At a median followup of 36.9 months (range, 3.3 to 181.5 months), the 5-year overall survival (OS) and disease-free survival (DFS) were 75.5% and 68.7%, respectively. With respect to treatment group, the 5-year OS and DFS in the RT and SRT groups did not differ significantly (OS, 68.7% vs. 80.5%, p=0.601; DFS, 63.1% vs. 73.1%, p=0.653). In multivariate analysis, OS differed significantly according to p16 expression (p16-negative vs. p16- positive; hazard ratio [HR], 0.145; 95% confidence interval [CI], 0.025 to 0.853; p=0.033). Regarding DFS, p16 expression (p16-negative vs. p16-positive; HR, 0.164; 95% CI, 0.045 to 0.598; p=0.006) showed a significant effect in multivariate analysis. Functional defects (late grade ≥ 3 dysphagia or voice alteration) were more frequently reported in the SRT than in the RT group (16.1% vs. 2.2%, p=0.021).
Conclusion
Despite advanced disease, patients in the RT group showed comparable survival outcomes and better functional preservation than those in the SRT group.

Citations

Citations to this article as recorded by  
  • Treatment de‐escalation for HPV+ oropharyngeal cancer: A systematic review and meta‐analysis
    Fausto Petrelli, Andrea Luciani, Antonio Ghidini, Sara Cherri, Paolo Gamba, Marta Maddalo, Paolo Bossi, Alberto Zaniboni
    Head & Neck.2022; 44(5): 1255.     CrossRef
  • Ginsenoside Rd inhibits migration and invasion of tongue cancer cells through H19/miR-675-5p/CDH1 axis
    Lu CHANG, Dongxu WANG, Shaoning KAN, Ming HAO, Huimin LIU, Zhijing YANG, Qianyun XIA, Weiwei LIU
    Journal of Applied Oral Science.2022;[Epub]     CrossRef
  • Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Oral Cavity Cancer in the Era of Modern Radiation Techniques
    Tae Hyung Kim, In-Ho Cha, Eun Chang Choi, Hye Ryun Kim, Hyung Jun Kim, Se-Heon Kim, Ki Chang Keum, Chang Geol Lee
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Superficial circumflex iliac artery perforator flap for tongue reconstruction after hemiglossectomy for cancer: A case report
    Hong Loi Nguyen, Truong Phu M. Ho, Xuan Phu Tran, Thanh Xuan Nguyen
    Oral and Maxillofacial Surgery Cases.2021; 7(2): 100219.     CrossRef
  • Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
    Ambika Parmar, Michaelina Macluskey, Niall Mc Goldrick, David I Conway, Anne-Marie Glenny, Janet E Clarkson, Helen V Worthington, Kelvin KW Chan
    Cochrane Database of Systematic Reviews.2021;[Epub]     CrossRef
  • Larynx-preserving reconstruction after extended base of the tongue resection
    Hideki Kadota, Junichi Fukushima, Sei Yoshida, Kenichi Kamizono, Muneyuki Masuda, Satoshi Toh, Ryuji Yasumatsu, Torahiko Nakashima, Takashi Nakagawa
    Journal of Plastic, Reconstructive & Aesthetic Surgery.2020; 73(4): 740.     CrossRef
  • 9,984 View
  • 228 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Effect of Adjuvant Chemotherapy on Stage II Colon Cancer: Analysis of Korean National Data
Min Ki Kim, Daeyoun David Won, Sun Min Park, Taejung Kim, Sung Ryong Kim, Seong Taek Oh, Seung Kook Sohn, Mi Yeon Kang, In Kyu Lee
Cancer Res Treat. 2018;50(4):1149-1163.   Published online December 7, 2017
DOI: https://doi.org/10.4143/crt.2017.194
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Debates exist regarding the effectiveness of adjuvant chemotherapy for stage II colon cancer. This study aimed to investigate the current status of adjuvant chemotherapy and its impact on survival for Korean stage II colon cancer patients by analyzing the National Quality Assessment data.
Materials and Methods
A total of 7,880 patientswho underwent curative resection for stage II colon adenocarcinoma between January 2011 andDecember 2014 in Koreawere selected randomly as evaluation subjects for the quality assessment. The factors that influenced overall survival were identified. The high-risk group was defined as having at least one of the following: perforation/ obstruction, lymph node harvest less than 12, lymphovascular/perineural invasion, positive resection margin, poor differentiation, or pathologic T4 stage.
Results
The median follow-up period was 38 months (range, 1 to 63 months). Chemotherapy was a favorable prognostic factor for either the high- (hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.38 to 0.59; p < 0.001) or low-risk group (HR, 0.74; 95% CI, 0.61 to 0.89; p=0.002) in multivariate analysis. This was also the case in patients over 70 years of age. The hazard ratio was significantly increased as the number of involved risk factors was increased in patients who didn’t receive chemotherapy. Adding oxaliplatin showed no difference in survival (HR, 1.36; 95% CI, 0.91 to 2.03; p=0.132).
Conclusion
Adjuvant chemotherapy can be recommended for stage II colon cancer patients, but the addition of oxaliplatin to the regimen must be selective.

Citations

Citations to this article as recorded by  
  • Colon cancer: the 2023 Korean clinical practice guidelines for diagnosis and treatment
    Hyo Seon Ryu, Hyun Jung Kim, Woong Bae Ji, Byung Chang Kim, Ji Hun Kim, Sung Kyung Moon, Sung Il Kang, Han Deok Kwak, Eun Sun Kim, Chang Hyun Kim, Tae Hyung Kim, Gyoung Tae Noh, Byung-Soo Park, Hyeung-Min Park, Jeong Mo Bae, Jung Hoon Bae, Ni Eun Seo, Cha
    Annals of Coloproctology.2024; 40(2): 89.     CrossRef
  • Factors Affecting Recurrence and Survival in Stage IIA Colon Cancer Patients
    Mert Erciyestepe, Oğuzhan Selvi, Gülhan Dinç, Ahmet Emin Öztürk, Okan Aydın, Şermin Dinç Sonuşen, Tuğçe Kübra Güneş, Tugay Avcı, Sezai Vatansever, Emir Çelik, Muhammed Mustafa Atcı
    Oncology.2024; 102(12): 1009.     CrossRef
  • Postoperative chemotherapy use and survival in non-high-risk young and high-risk old-aged patients with stage II colon cancer
    Tian Jin, Yingshuang Zhu, Wei Lu, Chenqin Le, Lijuan Wang, Qian Xiao, Kefeng Ding
    Holistic Integrative Oncology.2023;[Epub]     CrossRef
  • Risk factors for recurrence in elderly patients with stage II colorectal cancer: a multicenter retrospective study
    Takuki Yagyu, Manabu Yamamoto, Akimitsu Tanio, Kazushi Hara, Ken Sugezawa, Chihiro Uejima, Kyoichi Kihara, Shigeru Tatebe, Yasuro Kurisu, Shunsuke Shibata, Toshio Yamamoto, Hiroshi Nishie, Setsujo Shiota, Hiroaki Saito, Takuji Naka, Kenji Sugamura, Kuniyu
    BMC Cancer.2022;[Epub]     CrossRef
  • The role of high-risk features in stage II colon cancer after surgical treatment
    Patricio Bernardo Lynn, Garrett Yoon, Terry Li, Meng Cao, Michael Grieco, H. Leon Pachter, Russell C. Langan, Patrick Hilden, Joanna Sesti, Jason Maggi
    Surgery Open Digestive Advance.2022; 7: 100054.     CrossRef
  • Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: Analysis of the National Cancer Database
    Pietro Achilli, Jacopo Crippa, Fabian Grass, Kellie L. Mathis, Anne‐Lise D. D'Angelo, Mohamed A. Abd El Aziz, Courtney N. Day, William S. Harmsen, David W. Larson
    International Journal of Cancer.2021; 148(1): 161.     CrossRef
  • Associations of P Score With Real-World Survival Improvement Offered by Adjuvant Chemotherapy in Stage II Colon Cancer: A Large Population-Based Longitudinal Cohort Study
    Qi Liu, Zezhi Shan, Dakui Luo, Sheng Zhang, Qingguo Li, Xinxiang Li
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Impact of Inadequate Number of Lymph Nodes Examined on Survival in Stage II Colon Cancer
    Qi Wu, Zhiyuan Zhang, Yijiao Chen, Jiang Chang, Yudong Jiang, Dexiang Zhu, Ye Wei
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Effect of Adjuvant Chemotherapy on Elderly Stage II High-Risk Colorectal Cancer Patients
    Yujin Lee, Inseok Park, Hyunjin Cho, Geumhee Gwak, Keunho Yang, Byung-Noe Bae
    Annals of Coloproctology.2021; 37(5): 298.     CrossRef
  • Elderly High-Risk Stage II Colorectal Cancer Patients: Candidates for Improving Outcome?
    Min Ki Kim
    Annals of Coloproctology.2021; 37(5): 267.     CrossRef
  • Efficacy and tolerability of adjuvant therapy in ≥70-year-old patients with T3N0M0 colorectal cancer: An observational study
    Abdullah Sakin, Nurgul Yasar, Suleyman Sahin, Serdar Arici, Saban Secmeler, Orcun Can, Caglayan Geredeli, Cumhur Demir, Sener Cihan
    Journal of Oncology Pharmacy Practice.2020; 26(3): 619.     CrossRef
  • Postoperative chemotherapy improves survival in patients with resected high‐risk Stage II colorectal cancer: results of a systematic review and meta‐analysis
    C. Simillis, H. K. S. I. Singh, T. Afxentiou, S. Mills, O. J. Warren, J. J. Smith, P. Riddle, M. Adamina, D. Cunningham, P. P. Tekkis
    Colorectal Disease.2020; 22(10): 1231.     CrossRef
  • Patient Selection for Adjuvant Chemotherapy in High-Risk Stage II Colon Cancer
    Chao Zhang, Songcheng Yin, Yuen Tan, Jinyu Huang, Pengliang Wang, Wenbin Hou, Zhe Zhang, Huimian Xu
    American Journal of Clinical Oncology.2020; 43(4): 279.     CrossRef
  • Mucinous Histology Might Be an Indicator for Enhanced Survival Benefit of Chemotherapy in Stage II Colon Cancer
    Yong Huang, Kuanxue Ge, Guangshun Fu, Junfeng Chu, Wei Wei
    Frontiers in Medicine.2020;[Epub]     CrossRef
  • Re-Evaluation of the Survival Paradox Between Stage IIB/IIC and Stage IIIA Colon Cancer
    Hongbo Li, Guangshun Fu, Wei Wei, Yong Huang, Zhenguang Wang, Tao Liang, Shuyun Tian, Honggang Chen, Wei Zhang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Evaluating the Guiding Role of Elevated Pretreatment Serum Carcinoembryonic Antigen Levels for Adjuvant Chemotherapy in Stage IIA Colon Cancer: A Large Population-Based and Propensity Score-Matched Study
    Qi Liu, Yongqiang Huang, Dakui Luo, Sheng Zhang, Sanjun Cai, Qingguo Li, Yanlei Ma, Xinxiang Li
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Adjuvant chemotherapy does not provide survival benefits to elderly patients with stage II colon cancer
    Kil-yong Lee, Ji Won Park, Ki-young Lee, Sangsik Cho, Yoon-Hye Kwon, Min Jung Kim, Seung-Bum Ryoo, Seung-Yong Jeong, Kyu Joo Park
    Scientific Reports.2019;[Epub]     CrossRef
  • The use of chemotherapy in older patients with stage II and III colon cancer: Variation by age and era of diagnosis
    Susan L. Green, David E. Dawe, Zoann Nugent, Winson Y. Cheung, Piotr M. Czaykowski
    Journal of Geriatric Oncology.2018;[Epub]     CrossRef
  • 9,262 View
  • 290 Download
  • 16 Web of Science
  • 18 Crossref
Close layer
Survival Nomograms after Curative Neoadjuvant Chemotherapy and Radical Surgery for Stage IB2-IIIB Cervical Cancer
Claudia Marchetti, Francesca De Felice, Anna Di Pinto, Alessia Romito, Angela Musella, Innocenza Palaia, Marco Monti, Vincenzo Tombolin, Ludovico Muzii, PierLuigi Benedetti Panici
Cancer Res Treat. 2018;50(3):768-776.   Published online July 19, 2017
DOI: https://doi.org/10.4143/crt.2017.141
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to develop nomograms for predicting the probability of overall survival (OS) and progression-free survival (PFS) in locally advanced cervical cancer treated with neoadjuvant chemotherapy and radical surgery.
Materials and Methods
Nomograms to predict the 5-year OS rates and the 2-year PFS rates were constructed. Calibration plots were constructed, and concordance indices were calculated. Evaluated variableswere body mass index, age, tumor size, tumor histology, grading, lymphovascular space invasion, positive parametria, and positive lymph nodes.
Results
In total 245 patients with locally advanced cervical cancer who underwent neoadjuvant chemotherapy and radical surgery were included for the construction of the nomogram. The 5-year OS and PFS were 72.6% and 66%, respectively. Tumor size, grading, and parametria status affected the rate of OS, whereas tumor size and positive parametria were the main independent PFS prognostic factors.
Conclusion
We constructed a nomogram based on clinicopathological features in order to predict 2-year PFS and 5-year OS in locally advanced cervical cancer primarily treated with neoadjuvant chemotherapy followed by radical surgery. This tool might be particularly helpful for assisting in the follow-up of cervical cancer patients who have not undergone concurrent chemoradiotherapy.

Citations

Citations to this article as recorded by  
  • Plasma-based proteomic and metabolomic characterization of lung and lymph node metastases in cervical cancer patients
    Yue Feng, Zijian Sun, Huan Zhang, Zhao Wang, Lichao Wang, Hui Ye, Xiaojing Zhang, Zhuomin Yin, Juan Ni, Jingkui Tian, Hanmei Lou, Xiaojuan Lv, Wei Zhu
    Journal of Pharmaceutical and Biomedical Analysis.2025; 253: 116521.     CrossRef
  • Analysis of prognosis and related influencing factors of different surgical approaches for early cervical cancer
    Lingling Ou, Lulu He, Qiaowen Bu, Hengying Wu, Bin Wen, Xiping Luo, Xiaoshan Hong
    Journal of Cancer Research and Clinical Oncology.2025;[Epub]     CrossRef
  • Dose prediction for cervical cancer in radiotherapy based on the beam channel generative adversarial network
    Hui Xie, Tao Tan, Hua Zhang, Qing Li
    Heliyon.2024; 10(18): e37472.     CrossRef
  • Systematic review and meta-analysis of prediction models used in cervical cancer
    Ashish Kumar Jha, Sneha Mithun, Umeshkumar B. Sherkhane, Vinay Jaiswar, Biche Osong, Nilendu Purandare, Sadhana Kannan, Kumar Prabhash, Sudeep Gupta, Ben Vanneste, Venkatesh Rangarajan, Andre Dekker, Leonard Wee
    Artificial Intelligence in Medicine.2023; 139: 102549.     CrossRef
  • Development and validation of radiomic signature for predicting overall survival in advanced-stage cervical cancer
    Ashish Kumar Jha, Sneha Mithun, Umeshkumar B. Sherkhane, Vinay Jaiswar, Sneha Shah, Nilendu Purandare, Kumar Prabhash, Amita Maheshwari, Sudeep Gupta, Leonard Wee, V. Rangarajan, Andre Dekker
    Frontiers in Nuclear Medicine.2023;[Epub]     CrossRef
  • Advanced cervical stump cancer after laparoscopic subtotal hysterectomy: a case report of imaging, laparoscopic staging and treatment approach
    Dimitrios Andrikos, Argyrios Andrikos, Antoine Naem, Olga Ebertz, Rajesh Devassy, Rudy Leon De Wilde, Michael Khamou, Harald Krentel
    BMC Women's Health.2023;[Epub]     CrossRef
  • Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature
    Linlin Liu, Xianbo Deng, Shuang Guo, Shouhua Yang
    Diagnostic Pathology.2023;[Epub]     CrossRef
  • Influence of the Clinical Nursing Pathway on Nursing Outcomes and Complications of Cervical Carcinoma Patients Undergoing Chemotherapy via PICC
    Hongxia Tang, Li Gao, Yahui Li, Zhiqian Zhang
    Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1.     CrossRef
  • Current and future direction in treatment of HPV-related cervical disease
    Niloofar Khairkhah, Azam Bolhassani, Reza Najafipour
    Journal of Molecular Medicine.2022; 100(6): 829.     CrossRef
  • Machine Learning of Dose-Volume Histogram Parameters Predicting Overall Survival in Patients with Cervical Cancer Treated with Definitive Radiotherapy
    Zhiyuan Xu, Li Yang, Qin Liu, Hao Yu, Longhua Chen, Claudia Marchetti
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Efficacy and safety of pembrolizumab on cervical cancer: A systematic review and single-arm meta-analysis
    Lin Qi, Ning Li, Aimin Lin, Xiuli Wang, Jianglin Cong
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
    Jing Liu, Guyu Tang, Qin Zhou, Weilu Kuang
    Radiation Oncology.2022;[Epub]     CrossRef
  • The comparative study for survival outcome of locally advanced cervical cancer treated by neoadjuvant arterial interventional chemotherapy or intravenous chemotherapy followed by surgery or concurrent chemoradiation
    Yi Sun, Gailing Li, Panpan Hai, Yuan Cao, Pin Han, Yuchen Liu, Jing Wen, Yuanpei Wang, Xiaoran Cheng, Fang Ren
    World Journal of Surgical Oncology.2022;[Epub]     CrossRef
  • Pembrolizumab for advanced cervical cancer: safety and efficacy
    Francesca De Felice, Elena Giudice, Giulia Bolomini, Maria Grazia Distefano, Giovanni Scambia, Anna Fagotti, Claudia Marchetti
    Expert Review of Anticancer Therapy.2021; 21(2): 221.     CrossRef
  • Nomograms predicting the overall survival and cancer-specific survival of patients with stage IIIC1 cervical cancer
    Yifan Feng, Ye Wang, Yangqin Xie, Shuwei Wu, Yuyang Li, Min Li
    BMC Cancer.2021;[Epub]     CrossRef
  • Comparison of therapeutic effects of chemo-radiotherapy with neoadjuvant chemotherapy before radical surgery in patients with bulky cervical carcinoma (stage IB3 & IIA2)
    Setareh Akhavan, Abbas Alibakhshi, Mahdieh Parsapoor, Abbas Alipour, Elahe Rezayof
    BMC Cancer.2021;[Epub]     CrossRef
  • Macleayins A From Macleaya Promotes Cell Apoptosis Through Wnt/β-Catenin Signaling Pathway and Inhibits Proliferation, Migration, and Invasion in Cervical Cancer HeLa Cells
    Chunmei Sai, Wei Qin, Junyu Meng, Li-Na Gao, Lufen Huang, Zhen Zhang, Huannan Wang, Haixia Chen, Chaohua Yan
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Nomogram Predicting Overall Survival in Patients with FIGO II to III Squamous Cell Cervical Carcinoma Under Radical Radiotherapy: A Retrospective Analysis Based on 2018 FIGO Staging
    Lele Zang, Qin Chen, Xiaozhen Zhang, Xiaohong Zhong, Jian Chen, Yi Fang, An Lin, Min Wang
    Cancer Management and Research.2021; Volume 13: 9391.     CrossRef
  • Prediction of early response to concurrent chemoradiotherapy in cervical cancer: Value of multi-parameter MRI combined with clinical prognostic factors
    Xiaomin Zheng, Weiqian Guo, Jiangning Dong, Liting Qian
    Magnetic Resonance Imaging.2020; 72: 159.     CrossRef
  • Calculating the overall survival probability in patients with cervical cancer: a nomogram and decision curve analysis-based study
    Guilan Xie, Ruiqi Wang, Li Shang, Cuifang Qi, Liren Yang, Liyan Huang, Wenfang Yang, Mei Chun Chung
    BMC Cancer.2020;[Epub]     CrossRef
  • SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines
    Xing Chen, Dongsheng Xiong, Liya Ye, Huichun Yang, Shuangshuang Mei, Jinhong Wu, Shanshan Chen, Ruoran Mi
    Cancer Chemotherapy and Pharmacology.2019; 83(4): 603.     CrossRef
  • Systemic therapy in cervical cancer: 30 years in review
    Michalis Liontos, Anastasios Kyriazoglou, Ioannis Dimitriadis, Meletios-Athanasios Dimopoulos, Aristotelis Bamias
    Critical Reviews in Oncology/Hematology.2019; 137: 9.     CrossRef
  • Adjuvant chemoradiotherapy versus radiotherapy in cervical cancer patients with intermediate-risk factors: A systematic review and meta-analysis
    Meng Li, Mengyang Hu, Yuanjian Wang, Xingsheng Yang
    European Journal of Obstetrics & Gynecology and Reproductive Biology.2019; 238: 1.     CrossRef
  • Neoadjuvant chemotherapy followed by radical hysterectomy for stage IB2-to-IIB cervical cancer: a retrospective cohort study
    Lei Li, Ming Wu, Shuiqing Ma, Xianjie Tan, Sen Zhong
    International Journal of Clinical Oncology.2019; 24(11): 1440.     CrossRef
  • Immune check-point in cervical cancer
    F. De Felice, C. Marchetti, I. Palaia, R. Ostuni, L. Muzii, V. Tombolini, P. Benedetti Panici
    Critical Reviews in Oncology/Hematology.2018; 129: 40.     CrossRef
  • 9,900 View
  • 397 Download
  • 31 Web of Science
  • 25 Crossref
Close layer
Clinical Outcomes of Proton Beam Therapy for Choroidal Melanoma at a Single Institute in Korea
Tae Wan Kim, Euncheol Choi, Jeonghoon Park, Dong-ho Shin, Su Kyung Jung, Susie Seok, Kwan Ho Cho, Joo-Young Kim, Dae Yong Kim, Tae Hyun Kim, Yang Kwon Suh, Yeon Joo Kim, Sung Ho Moon
Cancer Res Treat. 2018;50(2):335-344.   Published online April 19, 2017
DOI: https://doi.org/10.4143/crt.2017.070
AbstractAbstract PDFPubReaderePub
Purpose
This study retrospectively evaluated the clinical outcomes and complications of proton beam therapy (PBT) in a single institution in Korea and quantitatively analyzed the change in tumor volume after PBT using magnetic resonance imaging (MRI).
Materials and Methods
Twenty-four treatment-naïve patients who underwent PBT for choroidal melanoma between 2009 and 2015 were reviewed. Dose fractionation was 60-70 cobalt gray equivalents over 5 fractions. Orbital MRIs were taken at baseline and 3, 6, and 12 months after PBT and annually thereafter. The tumor volume was reconstructed and evaluated by stacking the tumor boundary in each thin-sliced axial T1-weighted image using MIM software.
Results
The median follow-up duration was 36.5 months (range, 9 to 82 months). One patient had suspicious local progression and two patients had distant metastasis. The 3-year local progression-free survival, distant metastasis-free survival, and overall survival rates were 95.8%, 95.8%, and 100%,respectively. Five Common Terminology Criteria for Adverse Event ver. 4.03 grade 3-4 toxicities were observed in four patients (16.7%), including one with neovascular glaucoma. The mean tumor volume at the baseline MRI was 0.565±0.084 mL (range, 0.074 to 1.610 mL), and the ratios of the mean volume at 3, 6, and 12 months to that at baseline were 81.8%, 67.3%, and 60.4%, respectively.
Conclusion
The local controlrate and complication profile after PBT in patientswith choroidal melanoma in Korea were comparable with those reported in a previous PBT series. The change in tumor volume after PBT exhibited a gradual regression pattern on MRI.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of proton radiotherapy in treating choroidal melanoma: a systematic review and meta-analysis
    Yuxin Miao, Tingwei Zheng, Qiuning Zhang, Meixuan Li, Qihang Lei, Qin Liu, Hongtao Luo, Huiling Bai
    Radiation Oncology.2025;[Epub]     CrossRef
  • Monte Carlo simulation of polymer phantoms in proton therapy for eye tumor treatment
    Engin Aşlar, Fatih Ekinci
    The European Physical Journal Plus.2025;[Epub]     CrossRef
  • Opportunities and challenges of upright patient positioning in radiotherapy
    Lennart Volz, James Korte, Maria Chiara Martire, Ye Zhang, Nicholas Hardcastle, Marco Durante, Tomas Kron, Christian Graeff
    Physics in Medicine & Biology.2024; 69(18): 18TR02.     CrossRef
  • Magnetic Resonance Imaging in the Clinical Care for Uveal Melanoma Patients—A Systematic Review from an Ophthalmic Perspective
    Myriam G. Jaarsma-Coes, Lisa Klaassen, Marina Marinkovic, Gregorius P. M. Luyten, T. H. Khanh Vu, Teresa A. Ferreira, Jan-Willem M. Beenakker
    Cancers.2023; 15(11): 2995.     CrossRef
  • When Is the Optimum Radiological Response to Proton Beam Therapy in Uveal Melanoma?
    Matthew Gillam, Glenn Ace Fenech, Oliver Chadwick, Jonathan Nairn, Vikas Chadha, Julie Connolly, Oliver Cram, Wilma Kincaid, Paul Cauchi
    Ocular Oncology and Pathology.2023; 9(5-6): 130.     CrossRef
  • Optimization of proton therapy eye-treatment systems toward improved clinical performances
    Eustache Gnacadja, Cédric Hernalsteens, Stewart Boogert, Quentin Flandroy, Carolina Fuentes, Laurence J. Nevay, Nicolas Pauly, Eliott Ramoisiaux, William Shields, Robin Tesse, Raphael Van Roermund, Marion Vanwelde
    Physical Review Research.2022;[Epub]     CrossRef
  • Who Will Benefit from Charged-Particle Therapy?
    Kyung Su Kim, Hong-Gyun Wu
    Cancer Research and Treatment.2021; 53(3): 621.     CrossRef
  • Uveal Melanoma: A Review of the Literature and Personal Experiences
    Yong Joon Kim, Christopher Seungkyu Lee, Sung Chul Lee
    Journal of Retina.2021; 6(2): 65.     CrossRef
  • Carbon Fiducial Markers for Tumor Localization in Stereotactic Irradiation of Uveal Melanoma
    Timothy T. Xu, Jose S. Pulido, Ian F. Parney, Cristiane M. Ida, Lauren A. Dalvin, Timothy W. Olsen
    Ocular Oncology and Pathology.2021; 7(5): 368.     CrossRef
  • Uveal Melanoma in Asians: A Review
    Pradeep Manchegowda, Arun D. Singh, Carol Shields, Swathi Kaliki, Parag Shah, Lingam Gopal, Pukhraj Rishi
    Ocular Oncology and Pathology.2021; 7(3): 159.     CrossRef
  • Preliminary Dosimetric Study of Proton Minibeam Radiation Therapy for the Treatment of Choroidal Melanoma
    Myeongsoo Kim, Sang Soo Kim, Haksoo Kim, Sung Ho Moon, Young Kyung Lim, Ui-Jung Hwang, Sang Hyoun Choi
    Journal of the Korean Physical Society.2020; 77(5): 447.     CrossRef
  • Visual outcomes of proton beam therapy for choroidal melanoma at a single institute in the Republic of Korea
    Su-Kyung Jung, Young-Hoon Park, Dong-ho Shin, Hak-Soo Kim, Jong-Hwi Jung, Tae-Hyun Kim, Sung Ho Moon, Vikas Khetan
    PLOS ONE.2020; 15(12): e0242966.     CrossRef
  • 12,168 View
  • 271 Download
  • 12 Web of Science
  • 12 Crossref
Close layer
Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses
Kyo Chul Koo, Jin Seon Cho, Woo Jin Bang, Seung Hwan Lee, Sung Yong Cho, Sun Il Kim, Se Joong Kim, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung
Cancer Res Treat. 2018;50(1):129-137.   Published online March 8, 2017
DOI: https://doi.org/10.4143/crt.2017.004
AbstractAbstract PDFPubReaderePub
Purpose
Studies comparing radical prostatectomy (RP) outcomes with those of radiotherapy with or without androgen deprivation therapy (RT±ADT) for prostate cancer (PCa) have yielded conflicting results. Therefore, we used propensity score-matched analysis and competing risk regression analysis to compare cancer-specific mortality (CSM) and other-cause mortality (OCM) between these two treatments.
Materials and Methods
The multi-center, Severance Urological Oncology Group registry was utilized to identify 3,028 patients with clinically localized or locally advanced PCa treated by RP (n=2,521) or RT±ADT (n=507) between 2000 and 2016. RT±ADT cases (n=339) were matched with an equal number of RP cases by propensity scoring based on age, preoperative prostate-specific antigen, clinical tumor stage, biopsy Gleason score, and Charlson Comorbidity Index (CCI). CSM and OCM were co-primary endpoints.
Results
Median follow-up was 65.0 months. Five-year overall survival rates for patients treated with RP and RT±ADT were 94.7% and 92.0%, respectively (p=0.105). Cumulative incidence estimates revealed comparable CSM rates following both treatments within all National Comprehensive Cancer Network risk groups. Gleason score ≥ 8 was associated with higher risk of CSM (p=0.009). OCM rates were comparable between both groups in the low- and intermediate-risk categories (p=0.354 and p=0.643, respectively). For high-risk patients, RT±ADT resulted in higher OCM rates than RP (p=0.011). Predictors of OCM were age ≥ 75 years (p=0.002) and CCI ≥ 2 (p < 0.001).
Conclusion
RP and RT±ADT provide comparable CSM outcomes in patients with localized or locally advanced PCa. The risk of OCM may be higher for older high-risk patients with significant comorbidities.

Citations

Citations to this article as recorded by  
  • External beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study
    Caroline M. van der Starre, Chris H. Bangma, Maarten J. Bijlsma, Alfons C.M. van den Bergh, Lambertus A.L.M. Kiemeney, Wietske Kievit, Kees Vos, Diederik M. Somford, Sally M. Wildeman, Katja K.H. Aben, Igle J. de Jong, Floris J. Pos, Berdine L. Heesterman
    BMC Cancer.2025;[Epub]     CrossRef
  • Japanese clinical practice guidelines for prostate cancer 2023
    Yasuo Kohjimoto, Hiroji Uemura, Masahiro Yoshida, Shiro Hinotsu, Satoru Takahashi, Tsutomu Takeuchi, Kazuhiro Suzuki, Hiroshi Shinmoto, Tsutomu Tamada, Takahiro Inoue, Mikio Sugimoto, Atsushi Takenaka, Tomonori Habuchi, Hitoshi Ishikawa, Takashi Mizowaki,
    International Journal of Urology.2024; 31(11): 1180.     CrossRef
  • Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review
    Berdine L. Heesterman, Katja K. H. Aben, Igle Jan de Jong, Floris J. Pos, Olga L. van der Hel
    BMC Cancer.2023;[Epub]     CrossRef
  • Risk factors for prostate-specific antigen persistence in pT3aN0 prostate cancer after robot-assisted laparoscopic radical prostatectomy: a retrospective study
    Jun Seop Kim, Jae Hoon Chung, Wan Song, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Change Jeong, Seong Il Seo, Hyun Moo Lee, Seong Soo Jeon
    Journal of Yeungnam Medical Science.2023; 40(4): 412.     CrossRef
  • Comparison of contrast-enhanced ultrasound targeted biopsies versus standard systematic biopsies for prostate cancer correction in different PSA value groups in rural China
    Dian Yuan Lu, Lan Liu, Li Shen, Jian Rong Cai, Li Xu, Li Hua Xiang
    Clinical Hemorheology and Microcirculation.2021; 77(3): 295.     CrossRef
  • Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis
    Benjamin A. Greenberger, Nicholas G. Zaorsky, Robert B. Den
    European Urology Focus.2020; 6(2): 404.     CrossRef
  • Long short-term memory artificial neural network model for prediction of prostate cancer survival outcomes according to initial treatment strategy: development of an online decision-making support system
    Kyo Chul Koo, Kwang Suk Lee, Suah Kim, Choongki Min, Gyu Rang Min, Young Hwa Lee, Woong Kyu Han, Koon Ho Rha, Sung Joon Hong, Seung Choul Yang, Byung Ha Chung
    World Journal of Urology.2020; 38(10): 2469.     CrossRef
  • Comparing Radiotherapy to Prostatectomy for High-Risk Prostate Cancer
    Benjamin A. Greenberger, James M. Taylor, Victor E. Chen, Robert B. Den
    The Cancer Journal.2020; 26(1): 29.     CrossRef
  • Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis
    Narihiko Hayashi, Kimito Osaka, Kentaro Muraoka, Hisashi Hasumi, Kazuhide Makiyama, Keiichi Kondo, Noboru Nakaigawa, Masahiro Yao, Yuki Mukai, Madoka Sugiura, Shoko Takano, Eiko Ito, Hisashi Kaizu, Izumi Koike, Masaharu Hata, Masataka Taguri, Yasuhide Miy
    World Journal of Urology.2020; 38(10): 2477.     CrossRef
  • Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review
    Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, Giorgio Gandaglia, Nicola Fossati, Brian Kelly, Raj Pal, Erik Briers, Philip Cornford, Maria De Santis, Stefano Fanti, Silke Gillessen, Jeremy P. Grummet, Ann M. Henry, Thomas B.L. Lam, Michael Lar
    European Urology.2020; 77(5): 614.     CrossRef
  • Updated evidence on oncological outcomes of surgery versus external beam radiotherapy for localized prostate cancer
    Satoru Taguchi, Kenshiro Shiraishi, Hiroshi Fukuhara
    Japanese Journal of Clinical Oncology.2020; 50(9): 963.     CrossRef
  • Comparing effectiveness of radical prostatectomy versus external beam radiotherapy in patients with locally advanced prostate cancer
    Xianghong Zhou, Kun Jin, Shi Qiu, Di Jin, Xinyang Liao, Xiang Tu, Xiaonan Zheng, Jiakun Li, Lu Yang, Qiang Wei
    Medicine.2020; 99(34): e21642.     CrossRef
  • Robot or radiation? A qualitative study of the decision support needs of men with localised prostate cancer choosing between robotic prostatectomy and radiotherapy treatment
    Allan ‘Ben’ Smith, Orlando Rincones, Mark Sidhom, Pascal Mancuso, Karen Wong, Megan Berry, Dion Forstner, Leslie Bokey, Afaf Girgis
    Patient Education and Counseling.2019; 102(7): 1364.     CrossRef
  • Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis
    Changhoon Song, Sang Jun Byun, Young Seok Kim, Hanjong Ahn, Seok-Soo Byun, Choung-Soo Kim, Sang Eun Lee, Jae-Sung Kim, Christopher J.D. Wallis
    PLOS ONE.2019; 14(4): e0215057.     CrossRef
  • 125I low‑dose‑rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer
    Zhien Zhou, Weigang Yan, Yi Zhou, Fuquan Zhang, Hanzhong Li, Zhigang Ji
    Oncology Letters.2019;[Epub]     CrossRef
  • Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy
    Do Kyung Kim, Kyo Chul Koo, Kwang Suk Lee, Yoon Soo Hah, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • 9,982 View
  • 348 Download
  • 17 Web of Science
  • 16 Crossref
Close layer
Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea
Hee Kyung Kim, Jun Soo Ham, Seonggyu Byeon, Kwai Han Yoo, Ki Sun Jung, Haa-Na Song, Jinhyun Cho, Ji Yun Lee, Sung Hee Lim, Hae Su Kim, Ji-Yeon Kim, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Se Kyung Lee, Soo Youn Bae, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat. 2016;48(4):1382-1388.   Published online March 11, 2016
DOI: https://doi.org/10.4143/crt.2015.423
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to assess the tumor characteristics and long-term clinical outcomes of adjuvant treatments after surgery with a curative aim for patients with breast cancer who are 65 years and older. Materials and Methods Patients with breast cancer who underwent curative surgery from 2000 to 2009 were analyzed (n=4,388). Tumor characteristics and survival outcome were compared by dividing the patients into two age groups (< 65 and ≥ 65 years old). The Kaplan-Meier method was used for comparison of survival rates by log-rank test, and a Cox regression model was used to examine the effect of variables.
Results
Among 4,388 patients with invasive breast cancer, 317 patients (7.2%) were 65 years or older and the median age of all patients was 47 years (range, 18 to 91 years). Tumor characteristics were similar between the two age groups, but the older patients were treated less often with adjuvant treatments. During a median follow-up period of 122 months, recurrence-free survival (RFS) was equivalent for patients 65 years and older compared to younger patients, but significantly worse in overall survival (OS) and breast cancer–specific survival (BCSS) (5-year OS, 94.3% vs. 90.5%; p < 0.001 and 5-year BCSS, 94.7% vs. 91.8%; p=0.031). In the multivariate model, age ≥ 65 years old was identified as an independent risk factor for OS and RFS. Conclusion Elderly breast cancer appeared to have worse outcomes with very low prevalence in Korea, despite similar tumor characteristics. More active adjuvant therapies would have a role for aggressive subtypes for fit, elderly patients.

Citations

Citations to this article as recorded by  
  • HISTOPATHOLOGICAL AND BIOLOGICAL BEHAVIOR OF BREAST CANCER IN ELDERLY KURDISH WOMEN
    Kamal Saeed, Shewaz Salih
    JOURNAL OF SULAIMANI MEDICAL COLLEGE.2023; 13(4): 11.     CrossRef
  • Analysis of the tumor characteristics in young age breast cancer patients using collaborative stage data of the Korea Central Cancer Registry
    Junyup Kim, Seri Hong, Jae Jun Lee, Young-Joo Won, Eun Sook Lee, Han-Sung Kang, Seeyoun Lee, Jai Hong Han, Eun-Gyeong Lee, Heein Jo, Hyun Hee Kim, So-Youn Jung
    Breast Cancer Research and Treatment.2021; 187(3): 785.     CrossRef
  • Survival outcomes in elderly Taiwanese women according to breast cancer subtype and lymph node status: A single-center retrospective study
    Kung-Hung Lin, Huan-Ming Hsu, Kuo-Feng Hsu, Chi-Hong Chu, Zhi-Jie Hong, Chun-Yu Fu, Yu-Ching Chou, Golshan Mehra, Ming-Shen Dai, Jyh-Cherng Yu, Guo-Shiou Liao, Jason Chia-Hsun Hsieh
    PLOS ONE.2021; 16(12): e0261258.     CrossRef
  • Could lymph node evaluation be eliminated in nearly 50% of women with early stage ER/PR positive breast cancer?
    Juan Ruiz, Gerson Maldonado, Elizabeth Ablah, Hayrettin Okut, Jared Reyes, Karson Quinn, Patty L. Tenofsky
    The American Journal of Surgery.2020; 220(6): 1417.     CrossRef
  • Overall survival of elderly patients with breast cancer is not related to breast-cancer specific survival: A single institution experience in Japan
    Haruko Takuwa, Wakako Tsuji, Fumiaki Yotsumoto
    Breast Disease.2018; 37(4): 177.     CrossRef
  • Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting
    Chiara Mandoj, Laura Pizzuti, Domenico Sergi, Isabella Sperduti, Marco Mazzotta, Luigi Di Lauro, Antonella Amodio, Silvia Carpano, Anna Di Benedetto, Claudio Botti, Francesca Ferranti, Anna Antenucci, Maria Gabriella D’Alessandro, Paolo Marchetti, Silveri
    Journal of Translational Medicine.2018;[Epub]     CrossRef
  • Do site and type of metastasis in breast cancer show a changing pattern with increased age? A cross comparison of clinicopathological characteristics between age groups
    Majid Akrami, Afrooz Sepahdar, Peyman Arasteh, Sedigheh Tahmasebi, Vahid Zangouri, Azam Askari, Babak Pezeshki, Abdolrasoul Talei
    World Journal of Surgical Oncology.2018;[Epub]     CrossRef
  • Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice
    Jessemae L. Welsh, Tanya L. Hoskin, Courtney N. Day, Elizabeth B. Habermann, Matthew P. Goetz, Judy C. Boughey
    Annals of Surgical Oncology.2017; 24(10): 2881.     CrossRef
  • Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer
    Qixing Tan, Qinghong Qin, Weiping Yang, Bin Lian, Qinguo Mo, Changyuan Wei
    Medicine.2016; 95(44): e5302.     CrossRef
  • 12,892 View
  • 156 Download
  • 8 Web of Science
  • 9 Crossref
Close layer
Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
Daniel Keizman, Keren Rouvinov, Avishay Sella, Maya Gottfried, Natalie Maimon, Jenny J. Kim, Mario A. Eisenberger, Victoria Sinibaldi, Avivit Peer, Michael A. Carducci, Wilmosh Mermershtain, Raya Leibowitz-amit, Rony Weitzen, Raanan Berger
Cancer Res Treat. 2016;48(1):281-287.   Published online March 5, 2015
DOI: https://doi.org/10.4143/crt.2014.289
AbstractAbstract PDFPubReaderePub
Purpose
Studies suggested the existence of a ‘trial effect', in which for a given treatment, participation in a clinical trial is associated with a better outcome. Sunitinib is a standard treatment for metastatic renal cell carcinoma (mRCC). We aimed to study the effect of clinical trial participation on the outcome of mRCC patients treated with sunitinib, which at present, is poorly defined.
Materials and Methods
The records of mRCC patients treated with sunitinib between 2004-2013 in 7 centers across 2 countries were reviewed. We compared the response rate (RR), progression free survival (PFS), and overall survival (OS), between clinical trial participants (n=49) and a matched cohort of non-participants (n=49) who received standard therapy. Each clinical trial participant was individually matched with a non participant by clinicopathologic factors. PFS and OS were determined by Cox regression.
Results
The groups were matched by age (median 64), gender (male 67%), Heng risk (favorable 25%, intermediate 59%, poor 16%), prior nephrectomy (92%), RCC histology (clear cell 86%), pre-treatment NLR (>3 in 55%, n=27), sunitinib induced hypertension (45%), and sunitinib dose reduction/treatment interruption (41%). In clinical trial participants versus non-participants, RR was partial response/stable disease 80% (n=39) versus 74% (n=36), and progressive disease 20% (n=10) versus 26% (n=13) (p=0.63, OR 1.2). The median PFS was 10 versus 11 months (HR=0.96, p=0.84), and the median OS 23 versus 24 months (HR=0.97, p=0.89).
Conclusions
In mRCC patients treated with sunitinib, the outcome of clinical trial participants was similar to that of non-participants who received standard therapy.

Citations

Citations to this article as recorded by  
  • Clinical characteristics and outcomes of patients enrolled in clinical trials compared with those of patients outside clinical trials in advanced gastric cancer
    Jae Joon Han, Jin Won Kim, Koung Jin Suh, Ji‐won Kim, Se Hyun Kim, Yu Jung Kim, Jee Hyun Kim, Jong Seok Lee, Keun‐Wook Lee
    Asia-Pacific Journal of Clinical Oncology.2019; 15(3): 158.     CrossRef
  • Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study
    Shinji Ohno, Hirofumi Mukai, Kazutaka Narui, Yasuo Hozumi, Yasuo Miyoshi, Hiroshi Yoshino, Hiroyoshi Doihara, Akihiko Suto, Motoshi Tamura, Takashi Morimoto, Hisamitsu Zaha, Takashi Chishima, Reiki Nishimura, Takashi Ishikawa, Yukari Uemura, Yasuo Ohashi
    Breast Cancer Research and Treatment.2019; 176(3): 631.     CrossRef
  • Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma
    Anna M Czarnecka, Paweł Sobczuk, Jan Korniluk, Marta Spychalska, Krzysztof Bogusz, Anna Owczarek, Anna Brodziak, Dominika Labochka, Barbara Moszczuk, Cezary Szczylik
    Future Oncology.2017; 13(1): 31.     CrossRef
  • Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis
    Xiaoyan Liu, Marta Fiocco, Jesse J. Swen, Henk-Jan Guchelaar
    Acta Oncologica.2017; 56(4): 582.     CrossRef
  • Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region
    Carsten Nieder, Mohsan A. Syed, Astrid Dalhaug, Adam Pawinski, Jan Norum
    Medical Oncology.2017;[Epub]     CrossRef
  • Overexpression of the YAP1 oncogene in clear cell renal cell carcinoma is associated with poor outcome
    Agnieszka Rybarczyk, Jakub Klacz, Agata Wronska, Marcin Matuszewski, Zbigniew Kmiec, Piotr M. Wierzbicki
    Oncology Reports.2017; 38(1): 427.     CrossRef
  • 11,457 View
  • 63 Download
  • 8 Web of Science
  • 6 Crossref
Close layer
Cancer Res Treat : Cancer Research and Treatment
© Korean Cancer Association.
Close layer
TOP